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Abstract
In the setting of liver transplantation, clinical trials and transplant registries regularly col-
lect repeated measurements of clinical biomarkers which may be strongly associated with a
time-to-event such as graft failure or disease recurrence. Multiple time-to-event outcomes are
routinely collected. However, joint models are rarely used. This thesis will describe impor-
tant considerations for joint modelling in the setting of liver transplantation. We will focus on
transplant registry data from the United States. We develop a new tool for joint modelling in
the context where a critical health event can be tracked in the longitudinal biomarker and often
presents as a non-linear trajectory with a sharp jump. We capture this non-linearity with a sin-
gle change-point longitudinal component that is linked to the survival model via random e↵ects
in a way that incorporates the size of this change, which is a novel way to use a sharp change in
the subject-specific random e↵ect as a linkage in a joint model. We also propose an alternative
to time dependent analysis of treatment e↵ects by using a joint survival outcome model with
a time-to-drug-failure event and a terminal event in graft failure that is more appropriate to
use in drug e↵ectiveness studies where subjects are discontinued from an immunosuppressant
(in favour of alternative treatment) due to health reasons. Modelling drug regime failures as a
time-to-event process has not been previously considered in transplant studies. We show that
this method shows a significant association of time-to-drug-failure with time-to-graft-failure,
whether applied with a longitudinal component or on its own in a joint survival outcome model.
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Chapter 1
Introduction
There are many areas of medicine where enrolment in a registry occurs as part of the health care
process. Data elements collected by registries often include both longitudinal and time-to-event
measurements. For example, in Canada, the United States and Europe, every patient receiving
a transplanted organ is documented in detailed registry databases that include baseline infor-
mation, adverse events, and regular follow up information from the time of wait-listing for
transplant until death. In Canada, the Canadian Organ Replacement Register (CORR) collects
detailed information on every person waitlisted for transplant, and follows them through their
transplant for the rest of their life. In the United States, the Scientific Registry for Transplant
Recipients (SRTR) fulfills a similar role. These databases include baseline information and
repeated measurements on health status and other information at specific times for data collec-
tion. Several of these organizations allow researchers to request data sets for research projects
and analysis. The Ontario Cancer Registry, the B.C. Cancer Agency Registry, and the New
York State Cancer Registry are three examples of mandatory enrolment databases in oncology
that capture every patient who has been diagnosed with cancer (excluding non-melanoma skin
cancer). The Ontario Mental Health Reporting System is a mandated database that collects
information on patients admitted to mental health beds in the province of Ontario including
follow up every three months for patients who are still in hospital. The New York State Car-
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diac Surgery Reporting System collects data on all patients undergoing coronary artery bypass
grafts and percutaneous coronary intervention in non-federal New York state hospitals.
Registry data o↵er a rich source of real-world information. Physicians and other decision-
makers appreciate the external validity gained through analysis of such administrative data.
Randomized clinical trials often exclude patients with challenging comorbidities and as a con-
sequence, conclusions reached may be restricted to a specific population group. Analyses of
observational data from registries may complement the findings from clinical trials, adding
valuable insight.
In transplantation research, the use of joint outcome modelling techniques seems appropri-
ate for many situations, especially since there is much more data collected and available than
is commonly utilized beyond a typical survival analysis. And yet, in a field where so much has
been published on aspects of survival post-transplantation, surprisingly little work has been
done in transplant analyses using a joint outcome model to simultaneously incorporate both
longitudinal information available and the time-to-event data. Only Liu et al. [2004] examined
recurrent hospitalization events jointly with survival in kidney transplant candidates using data
from the SRTR in a paper that was influential in the field of joint outcome modelling. Longi-
tudinal covariate history can a↵ord much insight on the progression of graft status after liver
transplant, and statistical methods are available which can incorporate the trajectory for the
longitudinally collected data into the hazard function of a survival event such as graft failure or
death. There are many other time-to-event applications in transplantation research where the
use of joint outcome modelling techniques could prove useful, such as drug exposure and its
relationship to other key variables (e.g., time to new onset diabetes after transplant or time to
cancer recurrence or occurrence, or viral load and time to recurrence of Hepatitis C). The pri-
mary goal of this thesis is to establish that joint outcome modelling techniques are appropriate
and useful for transplant registry data analysis.
Alarm bells have been raised for some methods used in observational data. In particular,
some research examining overlapping data from the SRTR have come to opposing conclusions.
3There is a need to understand these issues, and potential sources of bias should be critically
examined. We propose that joint outcome modelling, while avoiding violation of statistical
assumptions, gains strength from employing more of the wealth of data that is available to
infer on survival outcome.
After liver transplantation, many laboratory values are assessed on a regular basis to give
information on the well-being of the patient. Physicians caring for these patients develop an
intuitive sense, based on research and practice, of the relationship of these longitudinal lab
values to the well-being of their patient. However, the collection of these biomarkers is widely
spaced. Often in the intervening time between data collection, a health event triggers a sharp
jump in the biomarker. We intend to assess whether we can use the information from such
sharp changes to better predict outcome. Interest lies in both understanding and interpreting
the meaning of within-subject patterns of change, as well as assessing the relationship between
the presence of a sharp jump in the biomarker and the risk of graft failure.
We are also interested in characterising the relationship between the two event processes
of graft failure and drug failure. When graft failure occurs, the subject either dies or im-
mediately receives a new liver transplant. Drug failure refers to the event where the initial
immunosuppressive regime is discontinued in favour of another one. Determining e cacy of
immunosuppressive treatment is not straightforward. Some treatments have a much higher rate
of discontinuation and some regimes may be given to a subset of patients with more serious
comorbidities.
In Chapter 2 we use a two-stage approach to investigate the relationship of a sharp change
in biomarker levels with the risk of graft failure in a joint model with a longitudinal and sur-
vival outcome. In Chapter 3 we apply a joint survival outcome model to the problem of drug
failure, which takes into account duration of treatment and allows us to include unmeasured
confounders through a frailty component. In Chapter 4 we further build on this joint survival
outcome approach by adding in a longitudinal component. The goal is to determine whether a
joint survival outcome model, in drug failure and graft failure, can add value to the analysis of
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drug e cacy. To answer these questions we will explore current techniques in joint modelling
using data on liver transplant recipients.
Chapter 1 Bibliography
Liu, Lei and Wolfe, Robert A and Huang, Xuelin. Shared frailty models for recurrent events
and a terminal event. Biometrics, 60(3): 744-756, 2004.
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Chapter 2
A joint model for change-point
longitudinal data with critical events
2.1 Introduction
Techniques for joint modeling and its application have been the subject of intensive research
in statistical methodology over the last twenty years. The field had its origins in the study
of the informative dropout process in the analysis of repeated outcomes, where the time of
dropout occurrence is modeled together with the repeated outcome. Important developments
grew out of the application to data from HIV/AIDS trials where survival was jointly modeled
with a longitudinal laboratory value, CD4 counts. These early models are described in detail by
Tsiatis and Davidian [2004], Molenberghs and Verbeke [2005] and Verbeke and Molenberghs
[2009]. The important developments can be traced from the two-stage approaches of Self and
Pawitan [1992] and others, to the likelihood based approaches of De Gruttola and Tu [1994]
and Henderson et al. [2000], as well as the latent class approach of Lin et al. [2002]. With
each year, the number of articles published on this topic grows enormously as new research
techniques flourish. Extensions to early approaches include multivariate models allowing for
multiple time-dependent covariates, first discussed by Song et al. [2002] and Lin et al. [2002].
In an important paper, Proust-Lima et al. [2009] described using a latent class approach to
model the link between the longitudinal covariates and the time-to-event. The predictive ability
of the longitudinal marker and tools for assessing accuracy of prediction have been studied by
6
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Pauler and Finkelstein [2002], Garre et al. [2008], Rizopoulos [2011], Rizopoulos [2012a],
Taylor et al. [2013], and Proust-Lima et al. [2014]. Various approximations to achieve faster
computational algorithms have been studied by Rizopoulos [2012b] and Barrett et al. [2015]
among others.
Early use of change-point models in the longitudinal component of joint models include
Faucett et al. [2002] and Pauler and Finkelstein [2002]. Both papers use a piecewise linear
mixed model with random change-point and a Cox proportional hazards model. In Jacqmin-
Gadda et al. [2006] the authors employed a piecewise polynomial mixed model with a random
change-point for the longitudinal marker and a log-normal model depending on the random
change-point for the time-to-event model. Here, the structure of three latent classes is used to
account for the correlation between the longitudinal trajectory (cognitive test scores) and the
risk of an event (dementia). Garre et al. [2008] proposed a change-point longitudinal compo-
nent in a joint model examining time to graft failure in kidney transplant recipients. A Bayesian
approach was taken with three latent classes and they linked the trajectory of reciprocal serum
creatinine for each latent class to the survival model using Cox proportional hazards. The
authors noted the computational di culty of this time-consuming approach using WinBUGS
(Lunn et al. [2000]). In a more recent paper, Ghosh et al. [2011] used a longitudinal process
with multiple change-points to model viral RNA data and a proportional hazards model for
the time to study dropout, clustering subjects according to estimated change-points, and then
linking the survival model based on each cluster. After applying a smooth transition function
to non-linear longitudinal data, Tapsoba et al. [2011] used a polynomial change-point model
with both a correction score and a conditional score method to link the proportional hazards
survival model.
These approaches to joint modeling with change-points use a combination of the pre-
change-point intercept random e↵ect and the slope random e↵ect before and after the change-
point as association parameters in the survival model. Both Faucett et al. [2002] and Pauler
and Finkelstein [2002] use the pre-change-point intercept random e↵ect and the pre- and post-
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change-point slope random e↵ects in their models. Jacqmin-Gadda et al. [2006] uses pre-
change-point intercept along with the pre-change-point slope and further slope coe cients
from a piecewise polynomial after the change-point. Garre et al. [2008] simplifies to only the
pre-change-point intercept random e↵ect and the post-change-point slope. Ghosh et al. [2011]
and Tapsoba et al. [2011] use the pre-change-point intercept random e↵ect and the change in
slope at the change-point, with Ghosh et al. [2011] also employing the pre-change-point slope
random e↵ect. None of these models examine the post-change-point intercept random e↵ect,
or the di↵erence in intercept random e↵ects before and after a change-point. This is of interest
in biomarkers where sharp jumps followed by stability can occur. An important element in
many studies where health su↵ers a sharp change which a↵ects survival is the subject-specific
measure of the change in a patient’s ‘benchmark’ biomarker level after a crisis as a critical pre-
dictor of survival, especially in situations where the longitudinal biomarker tends to be stable
around a unique baseline for each subject - a baseline which is determined by measured and
unmeasured (and possibly unknown) characteristics of each subject. The adverse event can be
tracked via marked non-linearity with a single change-point longitudinal component in a joint
model.
We take a novel approach by including the intercept random e↵ect after the change-point,
and a measure of the jump at the change-point. In our model, not only is this size of change con-
sidered, but also whether the change in the longitudinal trajectory is a health improvement or
a health deterioration. Since many biomarkers change sharply during the time of a crisis event
and the crisis can have a lingering e↵ect on the biomarker level, we believe that this modeling
framework is particularly useful for extracting relevant information from the longitudinal data.
We link the survival component through the random e↵ects in a way that incorporates the size
of the change in the subject-specific e↵ect, along with an indicator of health improvement or
deterioration which can be determined from the biomarker. This is a novel way to use a sharp
change in the subject-specific random e↵ect as a linkage in a joint model and an important
measure for a clinical context. This framework for analysis will be broadly useful in clinical
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practice settings such as transplant follow-up, where patients have frequent data collection of
longitudinal biomarkers. We demonstrate the ability of this framework to perform well on
long-term registry data where time-points are much further apart. The data reported here have
been supplied by the Minneapolis Medical Research Foundation (MMRF) as the contractor for
the Scientific Registry of Transplant Recipients (SRTR). The interpretation and reporting of
these data are the responsibility of the author(s) and in no way should be seen as an o cial
policy of or interpretation by the SRTR or the U.S. Government. In Section 2.2 we describe
the development of our single change-point joint model. In Section 2.3 we motivate the need
for accounting for these sharp changes in random e↵ects with an application to patient survival
after liver transplantation. We end with a final section containing a discussion and future work
in this area.
2.2 Model development
2.2.1 Joint longitudinal and survival submodel
In many medical longitudinal settings we see a sharp jump in previously stable levels of a
marker. While we may not know the precise cause of the jump, we can observe whether the
change resulted in a health improvement or a deterioration. We can draw information on the
magnitude of that change for an individual using a model which incorporates subject-specific
random e↵ects before and after the change. This model allows the trajectory of the longitudinal
marker to di↵er before and after the change-point, while assessing the degree of change on an
individual basis and how it a↵ects survival.
The linear random e↵ects model with one discontinuous change-point, having n subjects
with ni time-points ( j = 1, ...ni) for subject i = 1, .., n, with a single subject-specific change-
point ⌧i for the longitudinal marker yi j, is specified as
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yi j =
8>>>>>><>>>>>>:
 01 +  11mi j + x0i j 1 + b01i + b11imi j + ✏i j j = 1, ..., ⌧i
 02 +  12mi j + x0i j 2 + b02i + b12imi j + ✏i j j = ⌧i + 1, ..., ni
(2.1)
where  01 and  11 are, respectively, the intercept and slope before the change-point and  02 and
 12 are the new intercept and slope after the change-point; mi j is the time at which the longi-
tudinal measurement is taken; xi j are a set of covariates with respective vectors of regression
parameters  1 and  2, before and after the change-point. We assume that the random e↵ects bi
are normally distributed both before and after a change-point, but we allow for a change in these
subject-specific random e↵ects after the change-point, i.e. bi = (b01i, b11i, b02i, b12i) ⇠ N(0, D).
The variance-covariance matrix, D = (⌫1, ⌫2, ⌫3, ⌫4)I4x4, where I is a 4x4 identity matrix. The
measurement error ✏i j ⇠ N(0, 2) is assumed i.i.d. and independent of the random e↵ects.
The Weibull (↵,  ) model is commonly used for modelling time-to-event data and has prob-
ability density function
f (t| ,↵) =  ↵t↵ 1 exp(  t↵) (2.2)
where t is the survival time, and ↵ and   are the shape and scale parameters respectively. For
subject i we assume lifetime has a Weibull (↵,  i) such that
log( i) = z
0
i  +Wi (2.3)
where zi and   are covariates and corresponding regression coe cients. Wi are random e↵ects
which link the survival to the longitudinal model. We specify them as
Wi =⇢1 bˆ01i + ⇢2 bˆ02i
+ ⇢3 improve
n
( ˆ02 + bˆ02i)   ( ˆ01 + bˆ01i) + ⌧i
h
( ˆ12 + bˆ12i)   ( ˆ11 + bˆ11i)
io
+ ⇢4 deteriorate
n
( ˆ02 + bˆ02i)   ( ˆ01 + bˆ01i) + ⌧i
h
( ˆ12 + bˆ12i)   ( ˆ11 + bˆ11i)
io
+ ⇢5 bˆ11i + ⇢6 bˆ12i
(2.4)
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where the vector ⇢ are association parameters measuring the relationship between the vector of
random e↵ects bi and time to graft failure. Note that the parameter ⇢3 measures the association
between survival and the change in random e↵ect for those individuals with a change-point
and an associated improvement in health status where  improve is an indicator for improvement.
Improvement is defined as a decrease in the mean biomarker level after the change-point. We
discuss this in more detail in the next section. Similarly, ⇢4 measures the association between
survival and the jump at the change-point for those individuals with a change-point and associ-
ated deterioration in health status, where  deteriorate = 1  improve. The indicators   are similar to
those adopted by Pauler and Finkelstein [2002], who include an indicator variable for whether
a change-point occurred in an analysis of PSA biomarkers and their relationship to cancer re-
currence. We extend this to two indicators specifying whether the subject experienced a health
improvement or a health deterioration after the change-point. If no change-point occurred, both
indicators are zero.
2.2.2 Estimation and model comparison
It is challenging in a joint analysis to estimate a change-point in the longitudinal component.
For this reason, we are proposing a naive two-stage approach, where the existence and place-
ment of a change-point is determined ahead of time through a separate analysis of the longi-
tudinal component and these are fixed for inference in the joint model. We fit the longitudinal
model first and assume the change-point and whether or not there was an improvement or de-
terioration in health are fixed as estimated from the longitudinal analysis, and then we use this
framework in a joint analysis. The change-point was estimated using the methods described in
Killick and Eckley [2014]. Hence, the first stage analysis fits only the longitudinal component
and yields ⌧ˆi,  ˆimprove, and  ˆdeteriorate and these are fixed in the joint analysis.
No change-point was allowed between the first and second longitudinal observations to
assure identifiability of parameters in the model. Also, since the first measurement is taken
pre-transplant and the second measurement is six months after transplant, the e↵ect of having
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a transplant is such that almost everything has a change-point and it is di cult to separate out
the e↵ect of the drug during this time-frame. Thus, subjects who die early will not experience
a change-point. We account for this by including the   indicator variables of the presence
of a change-point in our survival model as covariates. This means that we treat those who
have no change-point the same way as those who die before a change-point can be estimated.
While there are di↵erences between these two groups, we cannot account for this in this model
without more frequent longitudinal observations. In the situation where everyone deteriorates,
⇢3 cannot be estimated. Thus if no improvements are expected, the term involving ⇢3 can be
omitted.
In the following mathematical descriptions, it is assumed that ⌧i,  improve, and  deteriorate
are known quantities. In practice, these are estimated through the first stage analysis of only
the longitudinal data. The likelihood from the joint model of both the longitudinal values
and the survival model is described here. Using the model for the longitudinal component in
equation (2.1), the density function of the longitudinal observations, the random e↵ects and the
covariates is
g(yi j|bi, 2, xi j)k(bi|D) (2.5)
where g(·) and k(·) are normal density functions. For the survival component, the conditional
density function f (ti| i,↵) is Weibull with hazard function hi(·) for the ith individual given by
hi(t|bi, yi j, zi) =  i↵( iti)↵ 1 (2.6)
where  i = exp(z
0
i  +Wi) as described in equation (2.3). Letting  i be the censoring indicator,
equalling 1 if the event occurs and 0 otherwise, and letting Ti be the observed time-to-event
variable, which is the minimum of the event time and censoring time, the joint likelihood can
then be expressed as,
L /
nY
i=1
niY
j=1
g(yi j|bi, 2, xi j) f (ti| i,↵) k(bi|D). (2.7)
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Estimation was carried out with a Bayesian approach and aMarkov chainMonte Carlo (MCMC)
algorithm in R (R Core Development Team [2014]) and JAGS (Plummer et al. [2003]) to obtain
estimates of the posterior distributions, with the priors specified in JAGS as non-informative:
 1k ⇠ N(0, 10000),  2k(k = 1, 2) ⇠ N(0, 10000), the components of  1 and  2 are each ran-
dom variables of independent N(0, 10000); similarly, the components of   ⇠ N(0, 10000),
↵ ⇠  (shape = 1, rate = 0.001), and ⇢1...⇢6 are i.i.d. N(0, 10000). The prior distributions for
the random e↵ects bi were specified as N(0, D) with the ⌫i as independent random variables
with priors ⇠ N(0, b) and  b was specified as  (shape = 0.001, rate = 0.001).
We ran 3 chains for 200,000 iterations with 100,000 burn-in. Convergence was judged by
the Brooks-Gelman-Rubin (BGR) convergence diagnostic (Brooks and Gelman [1998]). We
used the deviance information criterion (DIC) for model comparison. The DIC was proposed
by Spiegelhalter et al. [2002] as a Bayesian model selection tool which gives a measure of
goodness of fit while penalizing for the complexity of the model. Covariates were removed
from the model if the credible interval contained zero.
2.3 Application
The data we use to illustrate the utility of the model are taken from the Scientific Registry for
Transplant Recipients (SRTR), for those patients receiving their first cadaveric liver transplant
in the United States between January 1, 2000 and December 31, 2000. The SRTR data sys-
tem includes data on all donor, wait-listed candidates, and transplant recipients in the U.S.,
submitted by the members of the Organ Procurement and Transplantation Network (OPTN).
The Health Resources and Services Administration (HRSA), U.S. Department of Health and
Human Services provides oversight to the activities of the OPTN and SRTR contractors. A de-
tailed description of the database is available in Dickinson et al. [2003]. Longitudinal variables
collected include international normalized ratio (INR), bilirubin, albumin, creatinine, alkaline
phosphatase, aspartate aminotransferase (SGOT), and alanine aminotransferase (SGPT). The
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laboratory values are endogenous time-dependent variables. Endogenous variables are typi-
cally biomarkers measured on the subject under study. A more detailed definition of an en-
dogenous covariate is provided in Rizopoulos [2012a] and Diggle et al. [2002]. The features of
these variables, which are usually measured with error and at di↵erent times for each individ-
ual, dictate special considerations for analysis, making the use of a survival model with a time
dependent covariate inappropriate. Scientific considerations suggest the use of creatinine as
our longitudinal biomarker here since, besides being an indicator of kidney function and thus a
marker for the potentially toxic e↵ect of the immunosuppressive regime followed by transplant
recipients for life, creatinine can serve as a surrogate for a measure of general health.
Data time-points for collection of longitudinal creatinine (mg/dl) data are: immediately
pre-transplant (day of), six months post-transplant, one year post-transplant, and then yearly
on the anniversary of the transplant date. Creatinine values are collected on the day of graft
failure or patient death, however we do not include measurements taken at these times. Using
these values would introduce bias since the joint model assumes that the longitudinal measure-
ments are taken at uninformative time-points (Liu et al. [2007]). The joint model does include
immediate (day 0) pre-transplant lab measurements for all subjects.
We are interested in characterising the relationship between the event process and the tra-
jectories of the repeated measures, specifically whether there is value in this relationship from
a clinical perspective that could inform patient care (i.e., if there is a change-point detected,
should this inform the care?). Since the longitudinal measures are likely to be related to the
event of graft loss, we need to account for this in our analysis.
We assessed model fit on a separate validation data set also from SRTR (patients receiving
their first cadaveric liver transplant in the United States between January 1, 2001 and December
31, 2001).
All subjects selected for this analysis were age 16 and older, receiving a first liver transplant
with no other organs transplanted. There were 3207 subjects, with 1321 events (graft failure,
defined as death or retransplant). Of these, 1128 patients died and 193 were retransplanted.
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Note that, as is traditional in liver transplant studies, death from any cause with a functioning
graft is counted as a graft failure. Maximum follow up time was 11.4 years post transplant and
median follow up time was 8 years.
2.3.1 Results
In Figure 2.1 we show the Kaplan-Meier survival curve for the training dataset. In the longi-
tudinal component modeling log(creatinine), 738 subjects (23%) experienced a change-point.
Figures 2.2 through 2.4 show the longitudinal profile of log(creatinine) over time for randomly
selected patients who have more than three data points. We show those without a change-point,
those with a change-point and health improvement (i.e. a decrease in the biomarker) and those
with a change-point and health deterioration (an increase in the biomarker).
To select the variables for the components of the joint model we started with all covariates
deemed significant by recent literature in liver transplant survival models (e.g., Kamath et al.
[2001], Merion et al. [2005], Rana et al. [2013]) and proceeded with model selection. We con-
sidered immunosuppressive drugs that are commonly given after liver transplantation including
tacrolimus (TAC), cyclosporine (CYA), and sirolimus (SRL). We also considered the combi-
nations TAC + SRL and CYA + SRL as separate categories to allow for synergistic e↵ects,
and also the evaluation of SRL on its own without contamination of e↵ects of calcineurin in-
hibitors. We included only baseline immunosuppression, i.e. the drug recorded as maintenance
immunosuppression on the day of transplant. If this field was empty, we used the drug at time
of hospital discharge. We did not include use of steroids or induction therapies or concomitant
mycophenolic mofetil.
The Weibull (↵,  ) model (2.3) in the survival component was formulated where the vector
of covariates included Hepatitis C virus (HCV) status, hepatocellular carcinoma (HCC) status,
immunosuppressive drug at baseline, standardized age, standardized donor age, race (African
American or other), diabetic status, gender, whether a split liver was received, previous (re-
transplant) malignancy, use of a non heart-beating donor, whether the subject was in fulminant
16 Chapter 2. A joint model for change-point longitudinal data with critical events
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
time (year post transplant)
S
(t)
0 1 2 3 4 5 6 7 8 9 10
Figure 2.1: Kaplan-Meier survival curve (graft failure) for the training data.
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Figure 2.2: Longitudinal plots of log(creatinine) for four randomly selected patients who did
not experience a change-point.
18 Chapter 2. A joint model for change-point longitudinal data with critical events
0 2 4 6 8
0.
8
1.
0
1.
2
1.
4
1.
6
1.
8
Years post transplant
lo
g(
cr
ea
tin
in
e)
0 1 2 3 4 5 6 7
0.
00
0.
10
0.
20
Years post transplant
lo
g(
cr
ea
tin
in
e)
0 2 4 6 8
0.
0
0.
2
0.
4
0.
6
0.
8
Years post transplant
lo
g(
cr
ea
tin
in
e)
0 2 4 6 8 10
0.
2
0.
6
1.
0
1.
4
Years post transplant
lo
g(
cr
ea
tin
in
e)
Figure 2.3: Longitudinal plots of log(creatinine) for four randomly selected patients with a
change-point and improvement.
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Figure 2.4: Longitudinal plots of log(creatinine) for four randomly selected patients with a
change-point and deterioration.
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hepatic failure at the time of transplant, and indicators for improvement or deterioration in
health status ( improve and  deteriorate).
In the longitudinal component (2.1) the vector of covariates before the change-point in-
cludes the same covariates as in the survival component except for the addition of an indicator
of whether the subject was in fulminant hepatic failure at the time of transplant because of its
significant e↵ect on log(creatinine). Donor age was omitted since it did not significantly a↵ect
levels of log(creatinine).
We did not find that any baseline covariates continued to have a significant e↵ect on
log(creatinine) trajectory after a change-point. However, we only consider immunosuppressive
drug at baseline, i.e., we did not adjust for changes in immunosuppressive treatment. Table 2.1
shows the DIC values for some of the better-fitting survival sub-models, where the longitudinal
model was specified as in (2.1). A lower DIC is preferable. We see much higher DIC values
when the slope random e↵ects are included, and similarly for the indicator for health improve-
ment ( improve), indicating the added complexity from including these variables does not benefit
the model.
We found that a model without slope random e↵ects and where the size of the jump is
estimated by ( ˆ02 + bˆ02i)   ( ˆ01 + bˆ01i) fit the validation model better and had the lowest DIC.
In our example, this is likely because the slope parameters are so small. We also found that the
parameters ⇢2 and ⇢3 were not significant in the model. Hence, Wi becomes
Wi = ⇢1 bˆ01i
+ ⇢4  deteriorate
h
( ˆ02 + bˆ02i)   ( ˆ01 + bˆ01i)
i (2.8)
Results from the best fitted joint model are shown in Table 2.3. All of the variables shown
have a significant e↵ect on the survival model; note that the credible interval for both gender
and HCV contain zero, however they are significant in their interaction (i.e, there is increased
hazard for females who are HCV positive). Only one of the immunosuppressive treatments
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Linkage with survival sub-model DIC
⇢1 b01i + ⇢2 b02i + ⇢3  improve
h
( ˆ02 + b02i)   ( ˆ01 + b01i)
i
+⇢4  deteriorate
h
( ˆ02 + b02i)   ( ˆ01 + b01i)
i
+ ⇢5 b11i + ⇢6 b12i 82581
⇢1 b01i + ⇢2 b02i
+⇢4  deteriorate
h
( ˆ02 + b02i)   ( ˆ01 + b01i)
i
+ ⇢5 b11i + ⇢6 b12i 52187
⇢1 b01i+
+⇢4  deteriorate
h
( ˆ02 + b02i)   ( ˆ01 + b01i)
i
+ ⇢5 b11i + ⇢6 b12i 47831
⇢1 b01i + ⇢2 b02i + ⇢3  improve
h
( ˆ02 + b02i)   ( ˆ01 + b01i)
i
+⇢4  deteriorate
h
( ˆ02 + b02i)   ( ˆ01 + b01i)
i
40200
⇢1 b01i + ⇢2 b02i
+⇢4  deteriorate
h
( ˆ02 + b02i)   ( ˆ01 + b01i)
i
40542
⇢2 b02i + ⇢4  deteriorate
h
( ˆ02 + b02i)   ( ˆ01 + b01i)
i
39153
⇢1 b01i + ⇢4  deteriorate
h
( ˆ02 + b02i)   ( ˆ01 + b01i)
i
38335
Table 2.1: Bayesian model selection for the Weibull joint model.
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Table 2.2: Summary of initial drug therapies.
Initial treatment n (%)
TAC 2610 (81.4%)
SRL + TAC 175 (5.5%)
SRL 52 (1.6%)
CYA 333 (10.4%)
SRL + CYA 37 (1.2%)
(SRL) is significantly di↵erent from the reference drug TAC in terms of impact on survival,
however this result should be interpreted with caution since the numbers in this group are
small (see Table 2.2). We see that hazard of graft failure is increased for those who are HCC
positive, have a race of African American compared to all others, are diabetic, and increased
donor and recipient age. We tested all interactions of HCV status with other covariates and
found a significant interaction with donor age (higher donor age was associated with increased
risk of graft loss for both HCV positive and negative, with an additional risk for HCV positive
subjects), and gender (increased hazard for HCV positive subjects who are female compared
to no significant di↵erence in hazard by gender for HCV negative subjects). Hazard ratios for
the survival coe cients are shown in Table 2.4.
To put the results into context we may consider a subject who experienced a change-point
and a subsequent deterioration in health. Table 2.5 shows the minimum, mean and maximum
random e↵ect values from this group of subjects before and after the change-point. We see
that the hazard of graft loss for subjects who experienced a change-point and a subsequent
deterioration in health can be as high as 1.793, after taking into account the random e↵ects
(b01 and b02), the association parameters (⇢1 and ⇢4), and the change-point indicator  deteriorate.
For an individual i having the maximum values of the subject specific random e↵ects, this is
calculated as follows: exp(⇢1 b01i + ⇢4[( 02 + b02i)   ( 01 + b01i)] +  deteriorate) .
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Parameter Mean Standard error CI (lower) CI (upper)
Longitudinal submodel
intercept before c-p -0.142 0.034 -0.214 -0.078
intercept after c-p 0.454 0.020 0.415 0.494
slope before c-p 0.00003 0.000002 0.00002 0.00003
slope after c-p 0.000006 0.000005 0.000003 0.000002
age (standardized) 0.007 0.001 0.006 0.009
diabetes 0.047 0.020 0.007 0.086
fulminant failure 0.082 0.028 0.026 0.135
gender (F) -0.130 0.011 -0.152 -0.109
HCC -0.082 0.031 -0.144 -0.023
HCV -0.032 0.011 -0.053 -0.012
variance b01 0.072 0.067 0.076
variance b02 0.245 0.222 0.271
Survival submodel:
↵ (shape parameter) 0.901 0.020 0.858 0.946
intercept -9.075 0.259 -9.602 -8.615
HCV -0.135 0.150 -0.438 0.146
HCC 0.277 0.142 0.016 0.539
age(standardized) 0.010 0.003 0.004 0.016
donor age (standardized) 0.009 0.002 0.004 0.013
ixn: donor age x HCV 0.009 0.003 0.003 0.015
race (AA) 0.498 0.093 0.311 0.680
diabetes 0.430 0.093 0.247 0.609
gender (F) -0.138 0.083 -0.302 0.026
ixn: gender x HCV 0.319 0.120 0.088 0.555
previous malignancy 0.387 0.114 0.151 0.597
baseline treatment: TAC – – – –
SRL + TAC 0.041 0.120 -0.207 0.274 (ns)
SRL -0.645 0.282 -1.223 -0.118
CYA -0.021 0.092 -0.203 0.161(ns)
CYA + SRL 0.055 0.246 -0.203 0.161 (ns)
 improve -0.690 0.135 -0.975 -0.435
 deteriorate -0.765 0.177 -1.115 -0.435
Association parameters in the survival submodel:
⇢1 0.529 0.126 0.281 0.770
⇢4 0.690 0.168 0.339 1.008
Table 2.3: Posterior means for the log hazard, standard deviations and quantiles (ixn = interac-
tion).
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Parameter Hazard ratio
HCC 1.32
age (standardized) 1.01
donor age (standardized) 1.01
ixn: donor age x HCV 1.01
race (AA) 1.65
ixn: gender x HCV 1.38
diabetes 1.54
baseline trt - SRL 0.52
 improve 0.50
 deteriorate 0.47
association parameters
⇢1 1.70
⇢4 1.99
Table 2.4: Hazard ratios for significant covariates from the survival component of the joint
model. All elements except age and donor age are indicator variables, with absence being the
reference level (ixn = interaction).
Random e↵ect min mean max
b01 (random e↵ect before c-p) -0.959 -0.025 0.838
b02 (random e↵ect after c-p) -1.327 0.195 1.720
Table 2.5: Summary of values of random e↵ects before and after change-point for subjects
with deterioration in health status.
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2.3.2 Assessment of fit
We estimated each individual’s random e↵ects in the longitudinal model using all longitudi-
nal data from the validation data set (a new data set of 3192 subjects, receiving a first liver
transplant in 2001). In this validation set, 721 (23%) of subjects, experienced a change-point.
Then, using the saved parameter estimates from the training model, we tested the fit of our
model on the new data by estimating S (t) for each subject in the test data set. Figure 2.5 shows
the predicted mean survival curve for the test data using the joint model set versus its Kaplan-
Meier curve. This model follows the trajectory of the 95% confidence interval bounds for the
actual survival curve but is outside the upper bound. It does however, fit more closely than the
predictions on the test data than Cox proportional hazards model, one of the most commonly
used survival model in liver transplant research. The joint model fits better because it contains
the added information from the longitudinal component. By including association parameters
for the random e↵ects and the adjustment indicators for the change-point, the joint model al-
lowed for somewhat improved long-term fit. The authors recognize the limitation of this type
of prediction in registry data, which requires many years of retrospective longitudinal mea-
surements. Ideally, prediction would be applied in a clinical setting with much more frequent
biomarker measurements, updated in real-time. We found that, in comparing covariate e↵ects
from the joint model and the Cox proportional hazards model, the hazard ratios for significant
covariates were similar, interesting di↵erences are seen in interactions with HCV. Being female
was not significant in the joint model (except in the interaction with HCV), likely because the
joint model accounts for creatinine levels which are lower in women than men, thus adding
more information to the model. Since creatinine is an endogenous covariate, its use as a time-
dependent covariate would violate the statistical assumptions of the Cox proportional hazards
model, therefore a joint modeling approach is preferred. Table 2.6 shows a comparison of
hazard ratios and standard errors for our joint model vs the Cox proportional hazards survival
model.
We also show subject-specific comparisons of model fit using the validation data in Figures
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Figure 2.5: Mean predicted subject-specific survival curve for the validation dataset, showing
predictions for both the joint model and the Cox proportional hazards model.
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Figure 2.6: Subject-specific predictions of graft survival by model for a randomly selected
subject with change-point and graft failure (actual graft failure at 5.7 years). Subject is female,
HCV+, standardized age 0.51, standardized donor age -1.73, baseline treatment CYA.
2.6, 2.7, and 2.8. We selected our subject-specific comparisons randomly from subjects with
greater than 5 longitudinal data points in four categories: those with change-point and graft
failure, those with change-point and no graft failure, and those without a change-point and
with graft failure. Other details of the randomly selected subject covariate values are included
with the graph information. These curves were fitted using the random e↵ects calculated from
all of the longitudinal data in the validation data set. In both cases where graft failure oc-
curred (Figures 2.6 and 2.8), the joint model predicts a lower probability of graft survival than
the Cox model. In Figure 2.7, where the subject had a change-point but no graft failure, the
joint model predicts a lower probability of survival than the Cox model at time of censoring.
Here the joint model assigns a higher risk of graft failure due to a change-point occurrence at
four years. By using the joint model with log(creatinine) in the longitudinal component, we
have obtained better fit for long term survival after liver transplant. The joint model accounts
for the increased risk to graft failure when there is a change-point, or crisis, indicated in the
longitudinal biomarker.
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Figure 2.7: Subject-specific predictions of graft survival by model for a randomly selected
subject with change-point and no graft failure (censored at 10 years). Subject is female, HCV-,
African American, standardized age -0.45, standardized donor age -0.24, baseline treatment
TAC.
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Figure 2.8: Subject-specific predictions of graft survival by model for a randomly selected
subject with NO change-point and graft failure (actual graft failure at 9.5 years). Subject is
male, HCV+, standardized age -0.45, standardized donor age -0.24, baseline treatment TAC.
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2.4 Discussion
The fit of the survival model on the validation data shown in Figure 2.5 is a promising result for
liver transplant survival studies, where adequate model fit has been challenging. Most survival
analyses do not include testing model fit on a separate validation set, but where it does, results
are adequate for the short term only (Burroughs et al. [2006], Rana et al. [2013]) and long-term
validations are not attempted. By including longitudinal biomarkers in a joint model, we ob-
tain a clearer picture of long-term prognosis for transplant recipients, as well as the e↵ect on
survival of a sharp change in creatinine value. While a proper joint analysis would estimate
the existence of a change-point, it’s direction, and perform the joint survival analysis simul-
taneously, this ad hoc approach appears to work reasonably well and is not computationally
complex. Ideally, a joint model of this type would be applied in a clinical setting where much
more frequent longitudinal values o↵er the ability for real-time dynamic analysis of subject-
specific random e↵ects. Individual-specific shifts in the longitudinal marker could be linked to
the risk of graft failure in a way that is clinically relevant and e↵ective.
The broader implication for both observational studies and clinical trials is that joint mod-
eling should be the preferred method to determine parameter estimates and treatment e↵ects.
The collection of longitudinal data is standard and the inclusion of this additional data in the
survival analysis provides valuable information that results in greater e ciency of parame-
ter estimates (Klein et al. [2013]), even when data collection time-points are far apart, as in
registries. Real-time monitoring in clinical practice or clinical trials, with more frequent lon-
gitudinal measurements than we have available in the registry data, would result in meaningful
real-time random e↵ect calculations. Incorporation of sharp changes in the longitudinal data
allows the e↵ect of adverse events to provide additional information to the parameter estimates
and provides a better fit for long-term survival estimates.
The model would benefit from improvements to the fit early on, with the flexibility to ac-
commodate a steeper decline initially for the predicted mean survival (cf. Figure 2.5). Our
model certainly has limitations that cannot be resolved without more frequent data collection
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points, which would allow us to estimate a change-point in the first month after transplant.
With a finer time-scale we could distinguish between those who die before a change-point can
be estimated, and those who survive a long period with a stable biomarker and no change-point.
There are many avenues to explore investigating optimal change-point selection methods, and
the incorporation of estimation of the change-point as another individual level random e↵ect
in the joint model. More frequent data collection points would allow for study of the criterion
for change-point occurrence and the appropriate window size to inform clinical care. Smaller
time windows of data analysis with more frequent creatinine measurements would allow the
assessment of potential survival bias introduced by the fact that we require repeated measure-
ments in order to assess a change-point here, and our measurements are widely spaced. Since
researchers are often limited to using registry data with clinical trial or clinical care data not
readily available, we shall in future consider using the pre-transplant creatinine values avail-
able in the registry, which are collected on a more frequent basis while the subject is on the
waiting list, in a similar joint model. While it is di cult to predict technical failures or other
complications at the time of transplant, it is possible that the use of pre-transplant creatinine
in a joint model may provide a better fit for the first year post-transplant. Another avenue we
intend to explore in a forthcoming paper is the use of a mixture of Weibull models to account
for this operative mortality due to issues surrounding the transplant procedure that may not be
captured by our model. A time-varying e↵ect for the coe cient HCV is another avenue that
warrants investigation.
With transplant data, many possibilities are available for extension to a multivariate lon-
gitudinal component. However, the high computational cost when random e↵ects are of high
dimension makes this challenging. We found that omitting the slope random e↵ect and includ-
ing only the intercept and di↵erence random e↵ects allow for a model that is computationally
less complex. The direction of the slope is still captured by the use of indicator variables for
whether the subject has a mean increase or decrease in laboratory value before and after a
change-point. Our model was developed on a small data set, covering only one year of trans-
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plant data. With further refinements and using the larger available data set, the results would
provide more medical insight. Multiple change-points in joint models have been studied by
Ghosh et al. [2011] and are a natural extension to this model, with a possibly cumulative e↵ect
on graft failure.
There are many complexities to consider when studying immunosuppression after trans-
plant. For the sake of simplicity in developing the model we took a basic approach to immuno-
suppressive treatment here since we considered only the drug given at baseline and did not
include changes in drug regime. An improved approach will be discussed in the next chapter.
When a liver transplant recipient experiences a serious adverse event such as organ rejec-
tion, infection, drug toxicity, or cancer occurrence, it is likely that these events have a negative
e↵ect on survival since they can be life-threatening. It follows that severe events exhibit a lin-
gering e↵ect on longitudinal lab profiles. We use log(creatinine) as a proxy for general health
and we allow the occurrence of a sharp change in log(creatinine) to add more information to the
association between the longitudinal biomarker and the risk of graft loss. Traditional random
e↵ects measure the subject-specific change from the mean slope and/or intercept, and we are
incorporating more information on the size of the change from a subject’s own baseline. This
allows us to incorporate a feature of the biomarker trajectory into the linkage between the two
processes that conveys more information than just the current level of the biomarker.
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Variable Cox PH Joint Model
Hazard ratio Std error Hazard ratio Std error
HCC 1.31 0.14 1.37 0.14
age (standardized) 1.01 0.003 1.01 0.003
donor age (standardized) 1.01 0.002 1.01 0.002
ixn: donor age x HCV 1.01 0.003 1.01 0.003
diabetes 1.54 0.09 1.54 0.09
race (AA) 1.70 0.09 1.65 0.09
gender (F) 0.80 0.08 – –
ixn: gender x HCV 1.44 0.12 1.38 0.12
baseline trt - SRL 0.55 0.27 0.52 0.28
 improve – – 0.50 0.14
 deteriorate – – 0.47 0.18
⇢1 – – 1.70 0.13
⇢4 – – 1.99 0.17
Table 2.6: Hazard ratios and standard errors for significant covariates in the traditional Cox
proportional hazards model vs a joint model with change-point (ixn = interaction).
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Chapter 3
Lost in transplantation: sources of bias in
the analysis of transplant registry data
3.1 Introduction
In 2002, a randomized clinical trial examining use of hormone therapy in menopausal women
was terminated early because it failed to confirm findings of previous studies (using obser-
vational data) showing a protective e↵ect of hormone therapy (Prentice et al. [2005]). The
clinical trial, surprisingly, showed the opposite: an increased risk of coronary heart disease for
those taking hormone therapy. Herna´n et al. [2008] suggest that the source of inconsistent find-
ings stemmed in part from the assumption that there were no unmeasured confounders related
to treatment discontinuation. Methodological issues like this make assessment of statistical
results challenging, and comparison of results across studies frustrating. In transplant stud-
ies analyzing observational data for e cacy of immunosuppressive regimes, there is a similar
problematic situation. Added to this is the great disparity in the number of discontinuations by
regime. We are concerned that time-to-drug-discontinuation is incorporated inappropriately in
a typical survival analysis. We define the term time-to-drug-failure as the time when the initial
immunosuppressive regime was discontinued. We propose a two outcome joint survival model,
where we consider jointly time-to-drug-failure and time-to-graft-failure. Typically, duration of
treatment is not used in an analysis and this approach allows us to incorporate this useful data.
The use of frailty e↵ects in a joint modelling approach will account for some unmeasured
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confounders in treatment discontinuation. Frailties are the term for random e↵ects in the setting
of survival analysis, used to address unobserved heterogeneity. In fact, Wienke [2010] suggests
that the first use of a frailty was by Beard [1959] who used what he called a ‘longevity factor’ to
account for unobserved covariates in assessment of duration of life. While we cannot measure
unobserved covariates, frailties can be used to account for the e↵ect on time-to-event of some
of the unmeasured covariates and so reduce bias in the estimates (Klein and Moeschberger
[2003]). In a joint modelling context, we can use frailties to account for the correlation between
two time-to-event processes, such as time-to-drug-failure and time-to-death. By measuring the
individual frailty in one process, and using it as a link in a second (terminal) process we can
obtain a measure of the e↵ect of the first, non-terminal, time-to-drug-failure on the terminal
event, time-to-graft-failure. In doing so we account for heterogeneity caused by unmeasured
covariates (Wienke [2010]).
After liver transplant, immune suppression is necessary to prevent rejection of the grafted
organ. There are twomain immunosuppressive agents used, tacrolimus (TAC) and cyclosporine
(CYA). Since the 1990s many randomized clinical trials have compared the performance of the
two anti-rejection drugs, with TAC usually performing better in preventing rejection of the
transplanted liver and in reducing patient mortality, however resulting in more cases of new
onset diabetes post transplant (Shrum et al. [2016]). Accompanying the data from clinical tri-
als are transplant data registries that are maintained in many countries around the world. These
registries contain data for every patient who receives a transplanted organ, with detailed follow
up information until death. Statistical analyses comparing the e↵ectiveness of immunosup-
pressive agents after transplant using observational data have utilized a variety of approaches,
and further challenges have presented themselves since the arrival of a controversial new drug
sirolimus (SRL) in the late 1990s. SRL demonstrated immunosuppressive, anti-fungal and
anti-tumor activity through a mechanism of action that is di↵erent from TAC and CYA (Sehgal
[2003]). Some analyses have used a standard Cox proportional hazards survival model with
treatment changes included as a time-dependent covariate (Hadley et al. [1995], Watt et al.
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[2012]). However, assumptions of this model require that changes in the time-dependent co-
variate be unrelated to the outcome in a survival analysis. In transplantation this is not the
case, as one drug may be discontinued and an alternative chosen due to graft rejection or the
declining health of the patient for some other reason. Naive comparisons over time across non-
randomized treatment groups are also commonplace (Toso et al. [2010], Watt et al. [2012]). In
some cases (Toso et al. [2010]) only subjects remaining on a single treatment without switch-
ing are compared, therefore discarding much of the information in the data and leading to a
biased selection of healthy subjects. In addition, conflicting results have been reported on the
e↵ectiveness of immunosuppressive treatment with SRL after liver transplant using either ran-
domized clinical trial (RCT) data or registry data and it remains a contentious issue (Wiesner
et al. [2003], Shah et al. [2015]). Questions have been raised about e↵ectiveness of SRL for
subjects who are transplanted for either hepatitis C virus (HCV) or hepatocellular carcinoma
(HCC). Using registry data, Watt et al. [2012] found that SRL, whether given at baseline or
initiated later, was detrimental to patient survival in HCV positive subjects. Other studies such
as Wagner et al. [2010], McKenna et al. [2011] and Teperman et al. [2013] show (using various
data sources) that SRL improves survival in HCV positive subjects, limiting fibrosis occurrence
(the scarring of liver tissue that leads to cirrhosis). Resolving this question is of interest from
a clinical perspective since HCV (which often leads to HCC) is a leading indicator for liver
transplant. In this analysis approximately 55% of those transplanted for HCC are also infected
with HCV.
The generalizability and external validity o↵ered by the ‘real-world’ data of transplant reg-
istries is important and valued by the transplant community. Registries contain data from pa-
tients with comorbidities that often exclude them from a clinical trial. Analysis of registry
data complements the findings of RCTs and can provide insight for new research. However,
conflicting results and inconsistent methodology can be a source of frustration, and can lead
to dismissal of clinically relevant findings. Herna´n et al. [2008] notes that when findings be-
tween RCTs and observational studies disagree, it is tempting to blame lack of randomization
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in observational data. Herna´n et al. [2008] have further shown that observational studies can
produce conflicting results depending on the analytic approach employed. The data in the Sci-
entific Registry for Transplant Recipients (SRTR) is a frequent source of influential research
papers that have the power to change medical practice (e.g., Selck et al. [2008], who raised
important questions surrounding organ allocation for re-transplantation in recipients of organs
donated after cardiac death; and Locke et al. [2014] who demonstrated successful strategies
for the transplantation of HIV infected kidney transplant recipients). The divergent opinions
generated by analysis of data with strong overlap have also had an influence on practice, with
the results of Toso et al. [2010] demonstrating anti-cancer properties in SRL resulting in in-
creased use of SRL, followed by Watt et al. [2012] showing increased risk in HCV positive
subjects resulting in subsequent decreased use of SRL. The development and application of
unbiased statistical methods for analysis of this detailed and sizeable observational data set is
very important.
The goal of our investigation is to develop a method for assessing e↵ectiveness of immuno-
suppression after liver transplantation which can be employed for large datasets as occurs with
observational data from registries. We will identify risk factors for graft failure while tak-
ing into account the primary initial immunosuppression and time-to-failure of each commonly
used drug combination in a joint survival outcome model. By jointly modelling time-to-drug-
failure and time-to-graft-failure, we can account for the association between time on initial
drug therapy and graft survival. We also include baseline biomarker values as covariates. We
hypothesize that shorter time-to-drug-failure increases the risk of graft failure since more stable
patients do not change baseline treatment and thus experience improved outcomes. Time-to-
drug-failure serves as a surrogate indicator for many possible health events since someone
who is doing well after transplant is less likely to experience a change in immunosuppression.
Using two time-to-event processes for drug failure and graft survival has not been applied in
analyses of survival after liver transplant in registry data. Since the change in drug may be
directly related to health status, we propose that treating it as a time-to-event process in a joint
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model examining graft failure will provide less biased results than a Cox proportional hazards
model with treatment as a time-dependent covariate. A detailed review of the literature on joint
survival models can be found in Chapter 2.
3.2 Method
3.2.1 Data and variables
To illustrate our joint frailty model we used data from the Scientific Registry for Transplant Re-
cipients (SRTR), for those patients age 16 and older, receiving a first cadaveric liver transplant
in the United States between January 1, 2000 and December 31, 2006. We identified 23,980
subjects without missing data in the covariates under consideration, with 4,523 (19%) events
(graft failure, defined as death or retransplant) in the first three years post transplant. The pri-
mary endpoint was graft survival. We focus on graft survival rather than patient survival, since
graft survival is an important outcome for the limited resource of organ transplantation. Im-
munosuppressive therapy is recorded at baseline and discharge from hospital after transplant,
then at six months, and yearly. Exact dates for treatment changes are not given, so the data
are interval censored. To simplify the analysis we took the midpoint of the interval as the date
of treatment change. If a subject also died during the interval where a treatment change was
recorded, we took the midpoint of the start of the interval and the date of death as the day
of treatment change. If subjects were listed as receiving both TAC and CYA at baseline (an
impossible combination) and we could not verify baseline treatment, the subject was removed
from the analysis. The SRTR collects immunosuppressive therapy for only the first five years
after transplant. We chose to analyze baseline immunosuppression by combination (rather than
as any exposure or not, as in Watt et al. [2012] or Toso et al. [2010]), since this accounts for any
interaction or synergistic e↵ects between SRL and the calcineurin inhibitors (CYA or TAC).
This also allows us to see the e↵ects of SRL uncontaminated by other drugs.
Variables considered include induction immunosuppression (given only at baseline) includ-
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ing anti-CD25 antibody and thymoglobulin, adjuvant immunosuppression such as steroids,
mycophenolate mofetil (MMF) and azathioprine, again only whether or not they were given as
initial therapy.
Baseline covariates included were hepatocellular carcinoma (HCC) status, immunosup-
pressive drug regime at baseline (maintenance, induction and adjuvant), recipient age, donor
age, race (African American or other), diabetic status (insulin dependent Y/N), recipient gen-
der, donor gender, sex mismatch (Y/N), whether a split liver was received, whether the recipient
was in fulminant hepatic failure at the time of transplant, whether a non heart-beating donor
was used, recipient blood type, previous malignancy (prior to transplant), renal insu ciency
(defined as dialysis within the week prior to transplant (Y/N)), creatinine on day 0, bilirubin
on day 0, INR on day 0, and donor body mass index (BMI) .
3.2.2 Statistical methods
Here we present a joint survival outcomemodel with two time-to-event processes each of which
we model as Weibull as given by equation 2.2, but allowing di↵erent parameters and covariates
in each submodel. If a subject experiences a graft failure event, they are censored in the drug
failure model. For the ith individual, let tki represent lifetime, k = 1, 2, with t1i representing
time-to-drug-failure with shape parameter ↵1, and t2i representing time-to-graft-failure with
shape parameter ↵2. The scale parameter  ki can vary across individuals and event types. We
re-parameterize  ki as
log( ki) = z
0
ki k +  kci k = 1, 2 (3.1)
where zki and  k are the covariates and corresponding regression coe cients and where  1 = 1
and  2 =  . The ci are subject-specific frailty terms which link the two responses. In the graft
failure component,   measures the association between ci and time to graft failure.
Estimation was carried out with a Bayesian approach and a Markov chain Monte Carlo
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(MCMC) algorithm in R (R Core Development Team [2010]) and JAGS (Plummer et al.
[2003]) to obtain estimates of the posterior distributions, and with the priors specified in JAGS
as non-informative where the components of  1 and  2 are ⇠ N(0, 10000), ↵k ⇠ Unif(0, 1)
and ci ⇠ N(0, 1/ c), with  c ⇠ Unif(0, 10000). We ran 3 chains for 250,000 iterations with
220,000 burn-in, which took approximately 40 hours. Convergence was judged by the Brooks-
Gelman-Rubin (BGR) convergence diagnostic Brooks and Gelman [1998]. We used the de-
viance information criterion (DIC) for model comparison. Covariates were removed from the
model if the 95% credible interval contained zero. The final model for each cohort was chosen
after considering DIC as well as Cox Snell residuals for the graft survival component.
We compared the results of our joint model to traditional multivariate Cox proportional
hazards models for survival after liver transplant. We used a stepwise approach and included
the same covariates tested in the joint model. We also compared our results from the joint
survival model to a Cox model using propensity scores to account for use of SRL. Details of
this analysis are provided later. Lastly, we compare our results to a Cox proportional hazards
model where only those who remained on the same immunosuppression protocol for at least
six months after transplant were analyzed, as done in Toso et al. [2010], for example.
The data reported here have been supplied by the Minneapolis Medical Research Founda-
tion (MMRF) as the contractor for the Scientific Registry of Transplant Recipients (SRTR).
The interpretation and reporting of these data are the responsibility of the author(s) and in no
way should be seen as an o cial policy of or interpretation by the SRTR or the U.S. Govern-
ment. The SRTR data system includes data on all donor, wait-listed candidates, and transplant
recipients in the U.S., submitted by the members of the Organ Procurement and Transplan-
tation Network (OPTN). The Health Resources and Services Administration (HRSA), U.S.
Department of Health and Human Services provides oversight to the activities of the OPTN
and SRTR contractors. A detailed description of the database is available in Dickinson et al.
[2003].
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3.3 Results
3.3.1 Joint frailty model
Because of observed interactions between HCV and other covariates, we split the data into
HCV positive and negative cohorts. We know that HCV positive subjects fare more poorly than
the HCV negative cohort, due to increasing fibrosis in the transplanted organ due to recurrent
HCV. Recurrence of HCV is universal after transplant however the speed at which it progresses
depends on di↵erent factors such as viral load, donor age and other risks that are not completely
understood, although there is some evidence that this may include immunosuppressive regime
(McKenna et al. [2011], Howell et al. [2014]). There were 10,417 subjects (2,357 (22.6%) graft
failure events) who were HCV positive and 13,563 subjects (2,166 (16.0%) graft failure events)
who were HCV negative. Of these 23,980 total subjects identified for our analysis, 5,542 (23%)
changed their initial therapy within the first three years post-transplant. Table 3.1 shows the
number of subjects on each drug combination and how many changed therapies by year 3.
Table 3.2 shows the number of subjects on each immunosuppressive regime by HCV status.
These tables shows the great disparity in treatment switching among the various combinations.
A subject started on TAC alone is much less likely to discontinue baseline immunosuppression.
A subject started on the SRL + TAC combination is approximately 4 times more likely to
discontinue this combination than someone started on TAC alone. Treating drug failure as a
time-to-event process is important to acknowledge the information provided by this event and
to account for it in the analysis.
Figure 3.1 shows Kaplan-Meier curves for graft survival by initial drug therapy, separated
by HCV cohort. We can see that the HCV negative cohort enjoys better 3 year survival overall.
We show the same data by treatment, with 95% confidence intervals, in Figure 3.2. The SRL
as well as SRL in any drug combination have wide confidence intervals reflecting their sample
sizes. Figure 3.3 shows Kaplan-Meier curves for time to drug failure for each therapy. It is
interesting to compare patterns of drug changes by cohort. Here we see that SRL alone or in
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Table 3.1: Summary of the number of individuals (n) on initial drug therapies and the num-
ber and percent that changed (n changed (%)) from initial therapy within three years post-
transplant.
Initial treatment n n changed (%)
TAC 20,543 3,756 (18.3%)
SRL + TAC 882 676 (76.6%)
SRL 365 166 (45.5%)
CYA 1977 783 (39.6%)
SRL + CYA 213 161( 75.6%)
Table 3.2: Summary of initial drug therapies by HCV status.
HCV positive cohort
Initial treatment n (%)
TAC 8964 (86.1%)
SRL + TAC 363 (3.5%)
SRL 160 (1.5%)
CYA 841 (8.0%)
SRL + CYA 89 (0.9%)
HCV negative cohort
Initial treatment n (%)
TAC 11579 (85.4%)
SRL + TAC 519 (3.8%)
SRL 205 (1.5%)
CYA 1136 (8.4%)
SRL + CYA 124 (0.9%)
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Figure 3.1: Time-to-graft-failure, by initial immunosuppression.
combination (SRL + TAC, SRL + CYA) has the shortest time to drug failure. Of the 5,542
who terminated initial therapy within the 3 year study period, 2190 (40%) did so in the first
year post-transplant.
Results from the best fitting joint model for the HCV positive cohort are shown in Table
3.3. Most of the covariates listed in Table 3.3 have a significant e↵ect on graft survival or
time to drug failure. We include non-significant information for certain important variables to
show their credible intervals. A Bayesian 95% credible interval expresses the uncertainty of
our estimate and gives us the most plausible interval for our estimate, with a probability of 95%
(Lesa↵re and Lawson [2012]).
Baseline treatment was very significant in the time-to-drug-failure submodel. We see that
being on any initial treatment other than tacrolimus significantly shortens the time to change of
initial immunosuppressive therapy. The greatly increased risk of drug failure from initial im-
munosuppressive regime fits with the degree of treatment switching seen. Use of anti-CD25 an-
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Figure 3.2: Time-to-graft-failure, by initial immunosuppression, showing confidence intervals
for each cohort.
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Figure 3.3: Time-to-drug-failure, by initial immunosuppression.
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Table 3.3: Posterior means for the log hazard, hazard, std err and quantiles from the HCV
positive cohort joint model. (ns=not significant; AA = African American; F = female)
Parameter Mean Hazard Std err CI (lower) CI (upper)
Time-to-drug-failure submodel:
intercept -9.445 0.092 -9.623 -9.268
log(bilirubin) day 0 -0.208 0.067 -0.346 -0.080
log(INR) day 0 0.467 0.194 0.118 0.861
anti-CD25 antibody -0.345 0.145 -0.631 -0.062
baseline trt: TAC alone (ref) — — — —
SRL + TAC 7.066 0.291 6.487 7.646
SRL 3.167 0.366 2.448 3.878
CYA 2.711 0.175 2.372 3.062
CYA + SRL 7.033 0.532 5.988 8.086
 c 12.658 11.905 13.333
Time-to-graft-failure submodel:
↵ (shape parameter) 0.923 0.019 0.890 0.923
intercept -8.717 0.180 -9.084 -8.393
HCC 0.159 1.172 0.057 0.045 0.267
recipient age (decades) 0.0005 1.0005 0.003 -0.004 0.005 (ns)
donor age (decades) 0.018 1.018 0.001 0.016 0.021
race (AA) 0.416 1.516 0.064 0.289 0.540
gender (F) 0.208 1.231 0.048 0.109 0.300
diabetic 0.220 1.246 0.087 0.051 0.388
anti-CD25 antibody -0.145 0.865 0.065 -0.272 -0.016
log(creatinine) day 0 0.160 1.174 0.044 0.077 0.246
non heart-beating donor 0.392 1.480 0.104 0.188 0.589
previous malignancy 0.186 1.204 0.074 0.040 0.334
renal insu ciency 0.261 1.298 0.118 0.023 0.480
baseline trt: TAC (ref) – – – –
SRL + TAC -0.122 0.116 -0.359 0.110 (ns)
SRL 0.186 0.157 -0.127 0.478 (ns)
CYA 0.022 0.073 -0.121 0.171 (ns)
CYA + SRL -0.141 0.249 -0.656 0.310 (ns)
  0.065 1.067 0.008 0.050 0.080
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tibody induction therapy significantly lengthens time to initial drug failure (hazard ratio 0.70).
High INR and high bilirubin at time of transplant shortens time-to-drug-failure.
In the time-to-graft-failure component, we found that none of the immunosuppressive treat-
ments are significantly di↵erent from the reference drug TAC in terms of impact on graft sur-
vival, after taking into account covariates and the time-to-drug-failure frailty e↵ect. The model
is structured so that drug e↵ects are tested in comparison to tacrolimus, the most commonly
used treatment. Risk of graft failure is increased for female subjects, those who are diabetic
at transplant, those who are of African American race compared to all other races, for those
who had any previous malignancy, for those with renal insu ciency, for those who receive an
organ from a non heart-beating donor, for higher day 0 creatinine, for those with HCC, and for
increased donor age. The most dominant e↵ects are race, whether a non-heart-beating donor
was used, and renal insu ciency. Recipient age was kept in the graft failure model because it
improved DIC.
The individual frailty ci from the time-to-drug-failure component has a significant link
( ) between the two time-to-event submodels in the HCV positive cohort, where it increases
survival time for those with negative log frailties, and decreases survival time for those with
positive log frailties. Negative log frailties are associated with lower risk of a drug failure
event. Therefore, a change in baseline therapy is associated with shorter graft survival. This is
medically sensible since a change in treatment is often precipitated by an adverse event such
as rejection. Histograms of individual log frailties grouped by whether a drug failure occurred
are shown in Figure 3.4, and plots grouped by initial treatment are shown in Figure 3.5. The
value of the frailty ranges from approximately -7 to +9, so the estimated coe cient for the
individual frailty in the survival model, while small at 0.065 (hazard: exp(0.065 ⇥ ci)), can
have a large e↵ect depending on the value of the subject specific frailty, with a hazard ratio
ranging from a beneficial 0.63, to an increased hazard of 1.8. The variance of the subject-
specific frailty is 12.7, which shows there is a great deal of unobserved heterogeneity between
subjects. To put the results into context, Table 3.4 shows the estimated log frailties for each
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Figure 3.4: HCV positive cohort: Histograms of individual log frailties from time-to-drug-
failure model, by whether initial treatment was changed. Positive log frailties are associated
with increased risk of graft failure.
treatment combination, comparing the mean, minimum and maximum frailties of subjects who
did not change therapy to those who did. For the group on baseline therapy of TAC alone who
did change drug, the mean frailty shows the highest risk of graft failure (mean hazard ratio:
1.4), suggesting that subjects who do not do well on the ‘gold standard’ TAC are at greatest
risk of graft failure.
Results from the best fitted joint model for the HCV negative cohort are shown in Table
3.5. As in the HCV positive cohort, baseline treatment was very significant in the time-to-
drug-failure submodel. We see that being on any initial treatment other than TAC significantly
shortens the time to failure of initial immunosuppressive therapy. Interestingly, use of thy-
moglobulin induction therapy significantly shortens time to inital drug failure (hazard 1.5).
Anti-CD25 antibody, INR and bilirubin at time of transplant were not significant in the HCV
negative cohort for time-to-drug-failure.
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Figure 3.5: HCV positive cohort: Histograms of individual log frailties from time-to-drug-
failure model, by initial immunosuppression. Positive log frailties are associated with increased
risk of graft failure.
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Table 3.4: Summary of frailty e↵ects on time-to-graft-failure by initial drug therapy for the
HCV positive cohort.
Initial trt No drug failure:Mean (min, max) Hazard (min, max)
Had drug failure:
Mean (min, max) Hazard (min, max)
TAC -1.3 (-4.6, 1.4) (0.7, 1.1) 5.0 (3.2, 9.2) (1.2, 1.8)
SRL + TAC -4.4 (-6.9, -1.4) (0.6, 0.9) 1.3 (0.2, 3.9) (1.0, 1.3)
SRL -2.5 (-4.3, 0.1) (0.8, 1.0) 3.1 (2.0, 5.2) (1.1, 1.4)
CYA -2.4 (-5.1, 0.5) (0.7, 1.0) 3.4 (2.1, 7.6) (1.1, 1.6)
SRL + CYA -4.6 (-6.2, -1.9) (0.7, 0.9) 1.4 (0.5, 2.9) (1.0, 1.2)
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Figure 3.6: HCV negative cohort: Histograms of individual log frailties from time-to-drug-
failure model, by whether initial treatment was changed. Positive log frailties are associated
with increased risk of graft failure.
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Table 3.5: Posterior means for the log hazard, hazard, std err and quantiles from the HCV
negative cohort joint model. (ns=not significant; AA = African American; F = female)
Parameter Mean Hazard Std err CI (lower) CI (upper)
Time-to-drug-failure submodel:
intercept -9.716 0.053 -9.820 -9.614
thymoglobulin 0.384 0.168 0.071 0.714
baseline trt: TAC alone (ref) — — — —
SRL + TAC 6.291 0.229 6.491 7.371
SRL 3.480 0.320 2.855 4.111
CYA 2.415 0.141 2.138 2.688
CYA + SRL 6.510 0.434 2.138 2.688
 c 12.346 11.765 12.987
Time-to-graft-failure submodel:
↵ (shape parameter) 0.817 0.015 0.784 0.847
intercept -8.336 0.146 -8.624 -8.064
HCC 0.394 1.483 0.064 0.264 0.519
recipient age (decades) 0.008 1.008 0.002 0.005 0.012
donor age (decades) 0.010 1.010 0.001 0.007 0.012
race (AA) 0.394 1.483 0.074 0.249 0.535
gender (F) -0.246 0.782 0.048 -0.341 -0.151
diabetes 0.241 1.273 0.087 0.072 0.409
non heart-beating donor 0.324 1.383 0.047 0.232 0.415
previous malignancy 0.236 1.266 0.089 0.059 0.410
renal insu ciency 0.454 1.575 0.102 0.248 0.650
baseline trt: TAC – – – –
SRL + TAC 0.041 0.112 -0.184 0.257 (ns)
SRL -0.443 0.642 0.219 -0.910 -0.045
CYA 0.011 0.083 -0.154 0.168 (ns)
CYA + SRL 0.185 0.214 -0.248 0.584 (ns)
  0.085 1.089 0.008 0.071 0.101
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Figure 3.7: HCV negative cohort: Histograms of individual log frailties from time-to-drug-
failure model, by initial immunosuppression. Positive log frailties are associated with increased
risk of graft failure.
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In the time-to-graft-failure component, we found that being on SRL was significantly better
(hazard: 0.642) than the reference drug TAC in terms of impact on graft survival, after taking
into account covariates and the time-to-drug-failure frailty e↵ect (posterior mean: -0.443; 95%
credible interval: -0.910,-0.045). It is a beneficial dominant e↵ect even when taking into ac-
count frailty terms and all other variables in the model. For example, if we randomly select
an HCV negative cohort subject on SRL as initial therapy who did not change drug, we find
they have a frailty (ci) =  3.3 and the total e↵ect of SRL on graft failure has a hazard of
exp( 0.443 + 0.085 ⇥ ci) = 0.49. If we do the same for a subject started on SRL who did have
a drug failure event, we find they have ci = 3.2 and the e↵ect of SRL on graft failure has a
hazard of 0.84.
Similar to the HCV positive cohort, risk of graft failure is increased for those who are
diabetic at transplant, those who are of African American race compared to all other races,
for those who had any previous malignancy, for those with renal insu ciency, for those who
receive an organ from a non heart-beating donor, for those with HCC, and for increased donor
age. Recipient age also increased risk of graft failure in this cohort. Being female decreased
risk of graft failure (hazard ratio: 0.782), an opposite e↵ect to that seen in the HCV positive
cohort (hazard ratio: 1.231). We found that anti-CD25 antibody was not significantly protective
against risk of graft failure in this cohort. Creatinine on day of transplant also not significant.
The most dominant e↵ects in the HCV negative cohort were renal insu ciency, HCC and race.
The individual frailty ci from the time-to-drug-failure component also has a significant link
( ) between the two time-to-event submodels in the HCV negative cohort, where negative log
frailties are associated with lower risk of a drug failure event. The posterior mean was 0.085,
larger than in the HCV positive cohort. Histograms of individual log frailties for the HCV
negative cohort, grouped by whether a drug failure occurred are shown in Figure 3.6, and plots
grouped by initial treatment are shown in Figure 3.7. The value of the frailty ranges from
approximately -6.5 to +8.5, so the estimated coe cient for the individual frailty in the survival
model, while small at 0.085 (hazard: exp(0.085 ⇥ ci)), can have a large e↵ect depending on
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Table 3.6: Summary of frailty e↵ects on graft survival by initial drug therapy for the HCV
negative cohort.
Initial trt No drug failure:Mean (min, max) Hazard (min, max)
Had drug failure:
Mean (min, max) Hazard (min, max)
TAC -1.1 (-5.1, 1.6) (0.7, 1.1) 5.1 (3.7, 8.5) (1.4, 2.1)
SRL + TAC -4.3 (-6.4, -1.6) (0.6, 0.9) 1.4 (0.4, 3.9) (1.0, 1.4)
SRL -2.7 (-4.8, 0.6) (0.7, 1.1) 3.1 (1.9, 4.8) (1.2, 1.5)
CYA -2.2 (-4.8, 0.8) (0.7, 1.1) 3.6 (2.3, 6.5) (1.2, 1.7)
SRL + CYA -4.4 (-6.0, -1.3) (0.6, 0.9) 1.5 (0.5, 2.9) (1.0, 1.3)
the value of the subject specific frailty, with a hazard ratio ranging from a beneficial 0.58, to
an increased hazard of 2.06. The variance of the subject-specific frailty is 12.3, which shows
there is a great deal of unobserved heterogeneity between subjects (similar to the HCV positive
cohort). Table 3.6 shows these e↵ects for each treatment combination, comparing the mean,
minimum and maximum frailties of subjects who did not change therapy to those who did. The
situation is similar to the HCV positive cohort, with a slightly higher hazard seen here in the
negative cohort for the group on baseline therapy of TAC alone who have the highest risk of
graft failure if they also experience drug failure (mean hazard ratio: 1.5).
There are some di↵erences between the two cohorts. In the HCV positive cohort, anti-
CD25 antibody appears to extend the time-to-drug-failure and also has a beneficial e↵ect on
graft survival, however neither of these e↵ects are seen in the HCV negative cohort. Use of
thymoglobulin appears to speed up time-to-drug-failure in the HCV negative cohort whereas it
is not significant for HCV positive subjects. HCV negative subjects also see a beneficial e↵ect
on graft survival from the use of SRL that is not seen in the HCV positive cohort. The risk to
graft failure from HCC and renal insu ciency is greater in the HCV negative cohort.
3.3.2 Standard Cox model
We compared our joint frailty method to one using a standard Cox proportional hazard model
with no time-to-drug-failure component. Table 3.7 shows the results from the standard Cox
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Table 3.7: Results from a standard Cox proportional hazards model for the HCV positive
cohort.
Parameter Coe cient Hazard StdError p
HCC 0.156 1.169 0.057 0.006
donor age (decades) 0.019 1.019 0.001 < 0.001
log(creatinine) day 0 0.160 1.174 0.044 < 0.001
race (AA) 0.390 1.476 0.062 < 0.001
gender (F) 0.200 1.221 0.048 < 0.001
diabetes 0.219 1.245 0.086 0.011
non heart-beating donor 0.381 1.464 0.106 < 0.001
previous malignancy 0.199 1.220 0.075 0.008
renal insu ciency 0.250 1.284 0.116 0.031
anti-CD25 antibody -0.136 0.873 0.065 0.036
sex mismatch 0.101 1.106 0.047 0.032
baseline trt: TAC (ref) – – – –
SRL + TAC -0.107 0.899 0.118 0.364 (ns)
SRL 0.183 1.201 0.156 0.241 (ns)
CYA 0.031 1.032 0.074 0.676 (ns)
CYA + SRL 0.031 0.897 0.237 0.646 (ns)
model for the HCV positive cohort. None of the immunosuppressive treatments are signif-
icantly di↵erent from TAC, which matches the results we obtained in the joint model. The
standard Cox model identified sex mismatch as significantly increased hazard of graft failure,
which was not seen in the joint model.
The results from the HCV negative cohort for the standard Cox model without a joint
component are shown in Table 3.8. Again, they are similar to the results from the joint model
in terms of covariate e↵ects. We see a beneficial e↵ect of SRL alone on graft survival in the
HCV negative cohort, which matches the results from the joint model. The hazard is similar
(0.642 in the joint model vs 0.660 in the standard Cox model). Other research papers that treat
‘any SRL’ as one category would see this significant e↵ect washed out by the contamination
of the calcineurin inhibitors CYA and TAC. Receiving MMF at baseline, being in fulminant
hepatic failure at time of transplant, and high creatinine at baseline (day 0) were significant
predictors of graft failure in the standard Cox model but not in the joint model.
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Table 3.8: Results from a standard Cox proportional hazards model for the HCV negative
cohort.
Parameter Coe cient Hazard StdError p
donor age (decades) 0.010 1.010 0.001 < 0.001
log(creatinine) day 0 0.091 1.095 0.047 0.038
gender (F) -0.217 0.805 0.047 < 0.001
recipient age (decades) 0.007 1.007 0.002 < 0.001
HCC 0.394 1.483 0.065 < 0.001
non heart-beating donor 0.655 1.925 0.094 < 0.001
MMF at baseline -0.102 0.903 0.044 0.020
race (AA) 0.406 1.501 0.075 < 0.001
diabetic 0.237 1.267 0.086 0.006
fulminant hepatic failure -0.230 0.793 0.114 0.043
previous malignancy 0.230 1.259 0.089 0.009
renal insu ciency 0.386 1.472 0.107 < 0.001
baseline trt: TAC (ref) – – –
SRL + TAC 0.045 1.047 0.113 0.688 (ns)
SRL -0.416 0.660 0.210 0.048
CYA 0.016 1.016 0.079 0.838 (ns)
CYA + SRL 0.193 1.213 0.210 0.357 (ns)
For both cohorts, we were expecting to see more di↵erences between the standard Cox
model and the joint model, however the results are very similar. The Cox model gives almost
the same estimates and the standard errors are comparable.
3.3.3 Cox model with immortal time bias
We compared the results of our joint model to what the stable therapy method used by Toso
et al. [2010]. The method involves selection of only subjects who remain on the same immuno-
suppressive regime over a specified time period. This method can be criticized for including a
more healthy subset of patients resulting in a so-called immortal time bias (Di Martino et al.
[2015]), since subjects must survive for a 6 month time period without a drug failure event in
order to be included in the analysis. Toso et al. [2010] examined subsets of HCC positive sub-
jects versus HCC negative, but for the sake of comparison to our joint model, we will repeat
the analysis with our HCV cohorts. These groups have much overlap since those who have
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Table 3.9: Results from a Cox proportional hazards model for the HCV positive cohort showing
immortal time bias.
Parameter Coe cient Hazard StdError p
donor age (decades) 0.018 1.018 0.001 < 0.001
log(creatinine) day 0 0.186 1.204 0.048 < 0.001
gender (F) 0.181 1.199 0.054 < 0.001
HCC 0.164 1.178 0.063 0.009
non heart-beating donor 0.397 1.487 0.117 < 0.001
thymoglobulin 0.171 1.186 0.085 0.044
steroids at baseline 0.192 1.212 0.091 0.035
race (AA) 0.447 1.563 0.068 < 0.001
previous malignancy 0.165 1.179 0.085 0.054
sex mismatch 0.128 1.137 0.047 0.06
baseline trt: TAC (ref) – – –
SRL + TAC -0.343 0.709 0.198 0.084 (ns)
SRL 0.131 1.140 0.191 0.493 (ns)
CYA -0.007 0.993 0.090 0.938 (ns)
CYA + SRL -0.501 0.606 0.448 0.263(ns)
HCV often go on to develop HCC before transplant (Simonetti et al. [1992]). The results from
the stable Cox proportional hazards model for the HCV positive cohort are shown in Table 3.9.
We see that the results do not di↵er dramatically from either the joint model or the standard
Cox model, with some variables such as diabetic status and anti-CD25 antibody losing sig-
nificance, and others such as steroid and thymoglobulin use at baseline becoming significant
predictors. In Table 3.10, we do see the e↵ect of the immortal time bias in the HCV negative
cohort, where the benefit of being on SRL alone is exaggerated (hazard 0.392) and the p value
is much smaller (0.006).
3.3.4 Other sources of bias
We were initially unable to confirm results found in Watt et al. [2012] who found that SRL
presented increased risk in the HCV positive cohort. In our investigations we discovered three
more statistical issues that cannot be ignored when analyzing transplant data: contamination
of treatment e↵ects, failure to set one treatment as the reference level (control), and identifying
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Table 3.10: Results from a Cox proportional hazards model for the HCV negative cohort show-
ing immortal time bias.
Parameter Coe cient Hazard StdError p
donor age (decades) 0.011 1.011 0.001 < 0.001
log(creatinine) day 0 0.112 1.118 0.048 0.020
diabetic 0.304 1.356 0.096 0.002
gender (F) -0.227 0.797 0.053 < 0.001
age in decades 0.008 1.008 0.002 < 0.001
HCC 0.414 1.512 0.072 < 0.001
non heart-beating donor 0.648 1.912 0.107 < 0.001
MMF at baseline -0.114 0.893 0.049 0.019
split liver 0.619 1.857 0.216 0.004
race (AA) 0.458 1.580 0.083 < 0.001
previous malignancy 0.211 1.235 0.100 0.035
Renal insu ciency 0.441 1.554 0.115 < 0.001
baseline trt: TAC (ref) – – –
SRL + TAC -0.159 0.853 0.188 0.399 (ns)
SRL -0.936 0.392 0.334 0.006
CYA -0.110 0.896 0.096 0.252 (ns)
CYA + SRL -0.638 0.528 0.448 0.155 (ns)
living donor organs versus deceased donor organs.
In our attempt to replicate the results from Watt et al. [2012] we used a standard Cox Pro-
portional hazards model and a propensity score to account for non-randomized drug selection.
We calculated the propensity score in the same way asWatt et al. [2012] where a logistic regres-
sion model was employed to determine probability of being assigned an SRL-based treatment
given known covariate information, and subsequently this probability was included as a covari-
ate in the survival model. We also removed hepatitis B positive subjects, and those in fulminant
hepatic failure at the time of transplant, and we stratified the analysis by transplant centre as the
authors of the study did. Our analyses thus far have excluded subjects receiving a transplanted
organ from a living donor, due to the significant benefits to survival for this subset. We were
able to reproduce the results fromWatt et al. [2012] only if we included recipients transplanted
from both living and deceased donors in our analysis (10,936 subjects with 2,444 graft fail-
ures). However, it is important to note that Watt et al. [2012] did not include a covariate to
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account for living versus deceased donor.
Without requiring a propensity score, and without stratification by centre, we can reproduce
the result showing increased hazard of treatment with SRL for HCV positive subjects found in
Watt et al. [2012] by including both living and cadaveric donors without a covariate to adjust
for this distinction. We maintained our classification by drug combination rather than adopt
the one in Watt et al. which contaminates the e↵ect of treatment with SRL alone. Using the
covariates found significant in Watt et al. [2012], we show these results below in Table 3.11.
However, these results are biased since the covariate for living versus cadaveric donor has a
significant e↵ect on the model (see Table 3.12) and should be included. Table 3.12 also shows
an interaction trending toward significance between donor type and some baseline treatments.
This raises the question of drug e↵ectiveness in recipients transplanted from living donors
only. We performed a subset analysis of living donors in the HCV positive cohort from the same
time period (771 subjects with 144 graft failure events), and using a standard Cox proportional
hazards model we do find results which merit further investigation, specifically a greatly in-
creased hazard for those subjects receiving a transplant from a living donor, treated with SRL
alone at baseline (hazard 3.19, p value 0.013) and also for those on CYA alone (hazard (1.74,
p value 0.034). No other treatment e↵ects were significant. In the HCV negative cohort for
living donors only (1403 subjects, 199 graft failure events), the only significant treatment e↵ect
seen was an increased hazard for those on CYA alone (hazard 1.81, p value 0.019). However,
these subset results for living donors must be interpreted with caution since there were very
small numbers in the SRL and SRL combination groups. A larger scale study of living donor
data is warranted here.
3.4 Discussion
When analyzing registry data, one is often presented with challenging issues. Faced with
the disparity in treatment switching and with non-randomized treatment allocation, these chal-
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Table 3.11: Results from a standard Cox proportional hazards model for the HCV positive
cohort with both living and cadaveric donors included but not accounted for as a covariate.
This analysis uses covariates found significant in Watt et al. [2012].
Parameter Coe cient Hazard StdError p
donor age (decades) 0.018 1.018 0.001 < 0.001
log(creatinine) day 0 0.200 1.222 0.041 < 0.001
diabetic 0.256 1.292 0.084 0.002
gender (F) 0.198 1.219 0.046 < 0.001
HCC 0.218 1.244 0.056 < 0.001
baseline trt: TAC (ref) – – –
SRL + TAC -0.036 0.964 0.111 0.742(ns)
SRL 0.296 1.345 0.148 0.045
CYA 0.068 1.070 0.072 0.347 (ns)
CYA + SRL -0.027 0.973 0.231 0.905 (ns)
Table 3.12: Results from a standard Cox proportional hazards model for the HCV positive
cohort with both living and cadaveric donors, accounted for as a covariate.
Parameter Coe cient Hazard StdError p
living donor (LD) -0.204 0.815 0.101 0.043
donor age (decades) 0.018 1.018 0.001 < 0.001
log(creatinine) day 0 0.195 1.216 0.003 < 0.001
diabetic 0.250 1.284 0.084 0.003
gender (F) 0.202 1.224 0.046 < 0.001
HCC 0.216 1.241 0.056 < 0.0001
baseline trt : TAC (ref) – – –
SRL + TAC -0.069 0.934 0.117 0.560(ns)
SRL 0.234 1.263 0.156 0.134 (ns)
CYA 0.034 1.034 0.076 0.656 (ns)
CYA + SRL -0.492 0.949 0.237 0.825 (ns)
LD x TAC (ref) – – –
LD x SRL + TAC 0.388 1.475 0.351 0.269 (ns)
LD x SRL 0.829 2.290 0.484 0.087 (ns)
LD x CYA 0.476 1.610 0.255 0.063 (ns)
LD x CYA + SRL 0.492 1.636 1.032 0.633 (ns)
62 Chapter 3. Lost in transplantation: sources of bias
lenges can seem di cult to overcome. Some use propensity scores to account for non-randomization,
where a logistic regression model is employed to determine probability of being assigned a cer-
tain treatment based on known covariate information, and subsequently including this proba-
bility as a covariate in the survival model. However, the use of propensity scores is contentious
and may present a biased result if confounding or latent variables are not accounted for in the
model (Pearl [2003], Freemantle et al. [2013]). It also does not add any measure of time-on-
drug to the model. In the field of transplantation, where treatment assignment is subject to
an unmeasured assessment of the physician, use of propensity scoring in observational data is
ill-advised. Selection for treatment is likely to be based on unobservable factors such as the
intuitive sense of the transplant physician. These facts and the additional evidence that SRL is
less nephrotoxic than TAC and CYA led to its early use in circumstances where subjects were
burdened with poorer prognoses from the start, complicating analysis of observational data.
For these reasons, a joint outcome model such as the one we propose where latent factors may
be captured by individual frailties is preferable. Analyzing treatment failures as a time-to-event
process is a preferred approach in observational data analysis since it avoids discarding data,
or the violation of model assumptions. Analysis of the two time-to-event outcomes of drug
failure and graft failure using a joint model can account for dependence between the two pro-
cesses without making strong assumptions. We allow the important information contained in
the time-to-drug-failure component to influence the hazard of the time-to-graft failure compo-
nent. Transplant registry data, with 100% enrolment and follow up until death, is a valuable
and readily available data source that can provide insight into factors a↵ecting health outcomes
after liver transplant. The time-to-drug-failure acts as a surrogate for time to any adverse event
such as infection, rejection, cancer occurrence or other, that may be unreliably or not at all
collected in the registry data. This two outcome joint model describes the data structure well.
We believe that use of a straightforward joint survival outcome model is appropriate for two
reasons: first, clinical practice tells us that the association is strong between the drug failure and
graft failure processes, and second, less complex joint modelling techniques are more likely to
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be adopted in practice in this field. Joint modelling is not commonplace in analysis of registry
data for transplantation, yet despite readily available and appropriate data, it has only been used
in one application (Liu et al. [2004] for kidney transplant waiting list data).
Other sources of bias include use of treatment categories that do not allow for distinct
treatment groups to be examined, failure to account for living vs cadaveric donor organs, and
use of subjects who must survive in a stable treatment pattern in order to be included in the
analysis (immortal time bias). Use of improper methods in analyzing registry data leads to
anti-registry bias and also, more alarmingly, to changes in treatment patterns that may deprive
patients of valuable and beneficial treatment options.
A limitation of this data set is the lack of exact dates for treatment changes, and use of
the midpoint approximation is not ideal, however RCT data (with exact dates) are not readily
available for public analysis. Statistical bias related to the use of the midpoint is discussed in
Ru¨cker and Messerer [1988] and Odell et al. [1992]. To add recurrent events to the drug failure
model would involve the use of doubly interval censored data that are also correlated. Further-
more, data on subjects who change treatment more than once during a data collection interval
is not collected with su cient granularity in the SRTR to allow for a joint outcome analysis
with recurrent events in drug failure. We did not consider adjuvant drug therapies as additional
time-to-event processes; however this would be an interesting and clinically relevant extension
of this work. A prospective study, or retrospective with drug data review would be ideal so that
exact dates of termination can be evaluated. To include multiple time-to-event processes with
interval censored drug termination (the current state of SRTR immunosuppressive data) would
be unwieldy in a joint model. An application of joint modelling techniques to more detailed
RCT data with exact dates for drug data would provide greater understanding of the problem.
With collection of exact dates, many other time-to-event processes could be examined for their
association with graft failure, such as time to post-transplant diabetes, or time to cancer oc-
currence or recurrence. Additionally, greater statistical power can be obtained by considering
more than just the first drug failure in a recurrent event setting similar to Huang et al. [2011].
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The purpose of this paper was to address the source of bias behind di↵ering results when
certain traditional statistical methods are used, and to o↵er a novel approach which shows
promise. We also proposed a novel approach for drug e cacy using a joint survival outcome
model, and we show that the method can provide additional information in the assessment of
e cacy for what is a complex situation in transplantation.
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Chapter 4
Drug failure analysis in transplant
registry data
4.1 Introduction
In some fields of medicine, the dynamics of treatment and treatment failures require special
consideration in statistical analysis. Transplantation is one of these fields. Transplant recipi-
ents must maintain a lifelong immunosuppressive regime, and a failure of one regime requires
a change to an alternative drug. A failure in immunosuppressive treatment regime is on the
causal pathway to graft failure. Some analyses have used a standard Cox proportional haz-
ards survival model with treatment changes included as a time-dependent covariate (Hadley
et al. [1995], Watt et al. [2012]). However, assumptions of this model require that changes in
the time-dependent covariate be unrelated in this way to the survival outcome. Ignoring this
assumption may lead to biased results (Fisher and Lin [1999]). In transplantation, one drug
may be discontinued and an alternative chosen due to graft rejection or the declining health
of the patient for some other reason and so drug failures are typically indeed related to the
survival outcomes. The primary objective of this paper is to develop a method for analyzing
the e cacy of immunosuppressive treatment after liver transplant that accounts for potential
dependencies between drug failures and survival. Since the change in drug may be directly
related to health status, we propose that treating it as a time-to-event process in a joint outcome
model with time-to-graft-failure will provide less biased results. Modelling drug failures as a
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time-to-event process has not been considered in analyses of survival after organ transplant in
registry data.
We build on the method proposed in Chapter 3 by adding in the longitudinal component
from Chapter 2. While the existence of a change-point is an important aspect of the longitudinal
analysis, we do not include it here on account of the complexity it poses and the need for a
simpler trajectory for the longitudinal component. We are considering three year graft survival
and this limits the number of time-points available for building the longitudinal component.
The joint modelling of two time-to-event processes can be used for drug studies where the
duration on a particular drug and the survival of a patient on that drug is of interest, especially
in situations where the termination of the initial treatment drug is driven by the deteriorating
health status of the patient. There is an association between failures of immunosuppressive
treatment and graft survival, since treatment failures are likely triggered by another event that
increases the risk of death or graft failure (e.g., organ rejection, or cancer occurrence). We
suggest that jointly modelling graft survival and time-to-drug-failure in a joint survival outcome
model with frailty terms linking the two outcomes is preferable in this situation. We consider
an individual frailty to account for unobserved heterogeneity between patients. In addition,
we are able to add a longitudinal component to the joint model with the variable creatinine,
which is collected every year after transplant. Creatinine is important both as a general health
indicator, as well as an indicator of treatment drug toxicity which may also lead to treatment
switching.
Much of the research in modelling two time-to-event processes started with the joint anal-
ysis of recurrent events and a terminating event. These models allow for a recurrent and a ter-
minal event that are not independent. An important early paper in this area is Liu et al. [2004]
who proposed a Cox proportional hazards model with shared frailty for recurrent events and a
terminal event in an MCMC approach. The unobserved frailty in the model measures the latent
health status of the patient and it is related to both the recurrent event and the terminal event. A
shared frailty joint model accommodating multivariate longitudinal and bivariate time-to-event
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data with extension to a multivariate survival component was proposed by Chi and Ibrahim
[2006] in the setting of cure fractions. Other important work in the area of multiple time-
to-event processes includes Rondeau et al. [2007], where the authors propose a joint frailty
model using a non-parametric likelihood method. Both Liu et al. [2004] and Rondeau et al.
[2007] o↵er a thorough review of the history of research in this area from the 1990s to the mid
2000s. Another important paper by Rondeau et al. [2008] uses two additive shared frailties to
model trial and treatment heterogeneity in a meta-analysis. Liu and Huang [2009] is one of the
few papers to consider repeated longitudinal events and two or more time-to-event processes,
using a shared random e↵ects model. The hazard of the terminal event (death) depends on
both the longitudinal random e↵ects (CD4 counts) and the frailty term from the recurrent event
(infection). More recently, Musoro et al. [2015] proposed a shared frailty model for multiple
longitudinal outcomes and multiple repeated events (infections) without a terminal event using
an MCMC approach for inference.
The use of a joint modelling approach for modelling two event processes which did not
include a recurrent event, but one that must come before the other, was first undertaken by
Elasho↵ et al. [2007a] in a competing risks setting. Methods for multiple failure times in
the setting of competing risks and semi-competing risks data have become very popular, with
further papers from Elasho↵ et al. [2007b] followed by Williamson et al. [2008] and many
others. Most recently, the illness-death models of Xu et al. [2010], Han et al. [2014] and
Rouanet et al. [2015] have been applied to semi-competing risks data.
In this paper we utilize a joint model with a longitudinal component in log(creatinine),
and a bivariate survival model comprised of a time-to-drug-failure process and a time-to-graft-
survival process. This is a novel approach to drug e cacy analysis in transplantation. While
Liu and Huang [2009] considered a longitudinal outcome with a recurrent process and a ter-
minal event, a model with two survival events and a longitudinal component has not been pre-
viously considered. We hypothesize that higher creatinine levels are correlated with a greater
risk of drug failure and also with greater risk of failure of the transplanted liver. In examining
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three year survival, we do not use a change-point in the longitudinal process as in the previous
chapter as too few time-points are available in the longitudinal trajectory. We also hypothesize
that having a change from initial drug therapy is associated with a greater risk of graft failure.
In Section 4.2 we describe the development of our two time-to-event process joint model. In
Section 4.3 we motivate the need for this type of model in the analysis of graft survival after
liver transplantation.
4.2 Statistical methods
4.2.1 Joint longitudinal and survival submodels
The longitudinal component related to modelling the trajectory of log(creatinine) is a longitu-
dinal mixed e↵ects model that is linked to both survival models via random e↵ects. We use a
simplified version (without change-point) of the longitudinal component from Chapter 2, ex-
amining graft failure up to three years post transplant. Let yi j represent the longitudinal marker
log(creatinine) for subject i, i = 1, ..., n, at time-point mi j, j = 1, ...ni. The mixed e↵ects model
is
yi j =  0 +  1mi j + x0i j  + b0i + b1imi j + ✏i j j = 1, ..., ni; i = 1, ..., n (4.1)
where  0 and  1 are the intercept and slope; xi j are a set of covariates with respective vectors of
regression parameters  . The random e↵ects b0i, b1i are independent and normally distributed.
Let bi = (b0i, b1i). The variance-covariance matrix of bi, D = diag(⌫1, ⌫2). Then we assume the
measurement error ✏i j ⇠ N(0, 2) is independent of the random vector bi.
The longitudinal process influences two time-to-event processes: time-to-drug-failure and
time-to-graft-failure. For the ith individual, let tki represent lifetime, k = 1, 2, with t1i repre-
senting time-to-drug-failure with shape parameter ↵1, and t2i representing time-to-graft-failure
with shape parameter ↵2. The scale parameter  ki can vary across individuals and events types.
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We re-parameterize  ki as
log( ki) = z
0
ki k +Wki +  kci k = 1, 2 (4.2)
where zki and  k are the covariates and corresponding regression coe cients and where  1 = 1
and  2 =  . The Wki link the random e↵ects from the longitudinal model to the time-to-
drug-failure model, where W1i = ⇣1 bˆ0i + ⇣2 bˆ1i, and the time-to-graft-failure model (W2i =
⇢1 bˆ0i + ⇢2 bˆ1i). The ⇣ and ⇢ are association parameters measuring the relationship between the
vector of random e↵ects bi and the time-to-event processes. The ci are subject-specific frailty
terms which link the two responses. In the graft failure component,   measures the association
between ci and risk of graft failure. We assume that the repeated measures of creatinine are
correlated through the random e↵ects bi, and the hazard of the terminal event depends on the
longitudinal component and the time-to-drug-failure component through bi and ci respectively.
The frailty term ci is assumed independent of bi.
The data reported here have been supplied by the Minneapolis Medical Research Founda-
tion (MMRF) as the contractor for the Scientific Registry of Transplant Recipients (SRTR).
The interpretation and reporting of these data are the responsibility of the author(s) and in no
way should be seen as an o cial policy of or interpretation by the SRTR or the U.S. Govern-
ment. The SRTR data system includes data on all donor, wait-listed candidates, and transplant
recipients in the U.S., submitted by the members of the Organ Procurement and Transplan-
tation Network (OPTN). The Health Resources and Services Administration (HRSA), U.S.
Department of Health and Human Services provides oversight to the activities of the OPTN
and SRTR contractors. A detailed description of the database is available in Dickinson et al.
[2003].
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4.3 Application: A joint model for three year graft survival
after liver transplant using registry data
The goal of our investigation is to apply a new method for assessing e↵ectiveness of immuno-
suppression after liver transplantation, and to identify risk factors for graft failure while taking
into account the initial immunosuppression and time on a particular drug or drug combination.
Through joint modelling of the time-to-drug-failure and time-to-graft-failure processes, we can
account for the association between time on initial drug therapy and graft survival. Time-to-
drug-failure can be extended to a recurrent event format following the methods of Rondeau
et al. [2007], Liu and Huang [2009] or others, however we provide an example with the time
to first occurrence only, to provide a simplified model that establishes whether there is an asso-
ciation between creatinine, time on initial drug, and graft survival. We hypothesize that higher
creatinine values (i.e. larger random e↵ects) and a shorter time-on-initial-drug (i.e. larger
frailty) increase the risk of graft failure. The time-to-drug-failure frailty serves as a surrogate
indicator for many possible health events since someone who is doing well after transplant is
less likely to experience a change in immunosuppressive regime.
Estimation was carried out with a Bayesian approach and a Markov chain Monte Carlo
(MCMC) algorithm in R (R Core Development Team [2010]) and Just Another Gibbs Sam-
pler (JAGS, Plummer et al. [2003]) to obtain estimates of the posterior distributions, and
with the priors specified in JAGS as non-informative where the components of  1 and  2 are
⇠ N(0, 10000), ↵k ⇠ Unif(0, 1), and ⇢1, ⇢2 and ⇣1, ⇣2 are N(0, 10000). The ci ⇠ N(0, 1/ c),
with  c ⇠ Unif(0, 10000). The prior distributions for the random e↵ects bi were specified as
N(0, D) with the diagonal components of D ⇠ Unif(0, 10000). We ran 3 chains for 500,000
iterations with 400,000 burn-in, which took approximately 30 hours. Convergence was judged
by the Brooks-Gelman-Rubin (BGR) convergence diagnostic (Brooks and Gelman [1998]).
We used the deviance information criterion (DIC) for model comparison. Covariates were
removed from the model if the credible interval contained zero.
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We analyzed those patients age 16 and older, receiving a first cadaveric liver transplant
in the United States between January 1, 2000 and December 31, 2002. There were 10,015
subjects, with 1,757 (17.5%) events (graft failure, defined as death or retransplant) in the first
three years post-transplant. Immunosuppressive therapy is recorded at baseline and discharge
from hospital after transplant, then at six months, and yearly. Exact dates for treatment failures
are not given, so the data are interval censored. To simplify the analysis we took the midpoint
of the interval as the date of treatment change. If a subject also died during the interval where a
treatment change was recorded, we took the midpoint of the start of the interval and the date of
death as the day of treatment change. We do not use the data collected on the date of death or
retransplant, since this would introduce bias as only those who die have a measurement at this
unspecified time-point. If we could not determine baseline treatment, the subject was removed
from the analysis. We chose to analyze baseline immunosuppression by combination (rather
than as any exposure or not, as in Watt et al. [2012] or Toso et al. [2010]), since this accounts
for any interaction or synergistic e↵ects between SRL and the calcineurin inhibitors (CYA or
TAC). This also allows us to see the e↵ects of SRL uncontaminated by other drugs.
4.3.1 Results
The SRTR collects immunosuppressive therapy for only the first five years after transplant.
Most of the changes from initial therapy occur within the first year. Of the 10,015 subjects
without missing data, 2,468 (25%) changed their initial therapy within the first three years
post-transplant. Table 4.1 shows the number of subjects on each drug combination and how
many changed therapies by year 3. This table shows the great disparity in treatment switching
among the various regimes. Treating drug failure as a time-to-event process is important to
acknowledge the large amount of drug switching taking place in every group except TAC and
to account for it in the analysis. We only examine primary immunosuppressive therapy in
this model. For the sake of simplicity, induction therapy such as thymoglobulin or anti-CD25
antibody, and adjuvant immunosuppression such as steroids, azathioprine, or mycophenolate
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Table 4.1: Summary of the number of individuals (n) on initial drug therapies and the number
and percent that changed (n changed (%))from initial therapy within three years post-transplant.
Initial treatment n n changed (%)
TAC 8218 1554 (18.9%)
SRL + TAC 533 405 (76.0%)
SRL 149 26 (47.7%)
CYA 1026 416 (40.5%)
SRL + CYA 89 67 (75.3%)
mofetil, are not considered at this time.
Figure 4.1 shows Kaplan-Meier curves for graft survival by initial drug therapy. Those
started on CYA + SRL, SRL alone, or TAC alone enjoy the best survival. Figure 4.2 shows
Kaplan-Meier curves for time to drug failure for each therapy. Here we see that SRL alone or
in combination (SRL + TAC, SRL + CYA) has the shortest time to drug failure. Of the 2,468
who terminated initial therapy, 80% did so in the first year post-transplant.
We analyzed HCV positive and HCV negative subjects separately on account of non-
proportional hazards in this variable. There were 4,513 subjects (952 graft failure events)
who were HCV positive and 5,502 subjects (805 graft failure events) who were HCV nega-
tive. Recurrence of HCV is universal after transplant, however the speed at which it progresses
depends on di↵erent factors such as viral load, donor age and other risks that are not com-
pletely understood. There is growing evidence that this includes immunosuppressive regime
(McKenna et al. [2011], Howell et al. [2014]). Table 4.2 shows the number of subjects on each
immunosuppressive regime in each cohort.
Other variables considered included recipient and donor age in decades, recipient and
donor gender, gender mismatch between recipient and donor, donor BMI, whether a non-
heart-beating donor was used, hepatocellular carcinoma (HCC), previous malignancy (pre-
transplant), recipient race, recipient blood type, whether a split liver was received, and whether
the recipient was in fulminant hepatic failure at the time of transplant. Donor BMI was missing
in three subjects so the average was substituted. We also tested for covariate interactions with
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Figure 4.1: Graft survival by initial immunosuppression.
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Figure 4.2: Time-to-drug-failure, by initial immunosuppression.
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Table 4.2: Summary of initial drug therapies by HCV status.
HCV positive cohort
Initial treatment n (%)
TAC 3741(82.9%)
SRL + TAC 223 (4.9%)
SRL 69 (1.5%)
CYA 440 (9.7%)
SRL + CYA 40 (0.9%)
HCV negative cohort
Initial treatment n (%)
TAC 4477 (81.3%)
SRL + TAC 310 (5.6%)
SRL 80 (1.5%)
CYA 586 (10.7%)
SRL + CYA 49 (0.9%)
HCC status. We incorporated into our analysis longitudinal values of creatinine up to three
years post-transplant. Missing values were allowed in creatinine since the longitudinal trajec-
tory can still be estimated. There were a maximum of 5 longitudinal values (day of transplant,
6 months, year 1, year 2, year 3). The mean number of creatinine observations per subject was
3.3 and the median was 3.
We found a lower DIC when we did not include the slope random e↵ect from the longitu-
dinal component in both time-to-event processes, and so the models for both cohorts included
only an intercept random e↵ect in the longitudinal component of the model. This could be be-
cause the value of the overall slope  1 and its estimated random e↵ects are very small (0.006)
in the longitudinal model, or possibly because in our three year analysis there are not enough
repeated measurements of creatinine to improve the model when this random e↵ect is included.
The final model for each cohort was chosen after considering DIC as well as Cox Snell resid-
uals for the graft survival component.
Results from the best fitting joint model for the HCV positive cohort are shown in Table
4.3. Most of the covariates listed in Table 4.3 have a significant e↵ect on time-to-graft-failure
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or time-to-drug-failure. The covariate gender was kept in the longitudinal model because it
improved the DIC even though the credible interval contained zero.
The random e↵ect b0i was an important linkage term between the longitudinal and the graft
failure submodels. In the longitudinal component, we saw a lower log(creatinine) over time in
female subjects, while a higher log(creatinine) was seen in older subjects, those in fulminant
failure at time of transplant, those who were diabetic at transplant, and those with a higher
donor BMI.
The only covariate significant in the time-to-drug-failure submodel was treatment. Being
on any initial treatment other than TAC significantly shortens the time to change of initial
immunosuppressive therapy. The greatly increased risk of drug failure from initial immuno-
suppressive regime fits with the degree of treatment switching seen. The linkage parameter ⇣
was not significantly associated with to time-to-drug-failure.
In the time-to-graft-failure component, we found that none of the immunosuppressive treat-
ments are significantly di↵erent from the reference drug TAC in terms of impact on graft sur-
vival, after taking into account covariates and the time-to-drug-failure frailty e↵ect. The model
is structured so that drug e↵ects are tested in comparison to TAC, the most commonly used
treatment. Risk of graft failure is increased for those who are of African American race com-
pared to all other races, for those who had any previous malignancy, and for increased donor
age. We found no significant e↵ect for HCC status in the model, even with the variable for pre-
vious malignancy removed, and no interaction between initial drug therapy and HCC status.
The subject-specific intercept random e↵ect b0i from the longitudinal component has a
significant link with graft survival through the association parameter (⇢1), with a hazard ratio
of 1.567 for each one unit change in the random e↵ect. The random e↵ects themselves range
from -0.69 to 1.43, and so the hazard can be as beneficial as 0.73 for those with lower than
average creatinine levels, and as high as 1.90. When grouped by drug the random e↵ects do
not show any distinct patterns (see Figure 4.3).
The individual frailty ci from the time-to-drug-failure component has a significant link
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Figure 4.3: HCV positive cohort: Histograms of subject-specific intercept random e↵ects from
the longitudinal model, by initial treatment. Positive random e↵ects are associated with in-
creased risk of graft failure.
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through the association parameter   to the graft survival model in the HCV positive cohort,
where it increases survival time for those with negative log frailties, and decreases survival
time for those with positive log frailties. Negative log frailties are associated with a lower risk
of a drug failure event. Therefore, failure of initial therapy is associated with shorter graft
survival. This is medically sensible since a change in treatment is often precipitated by an
adverse event such as rejection. Histograms of individual log frailties grouped by whether a
drug failure occurred are shown in Figure 4.4, and plots grouped by initial treatment are shown
in Figure 4.5. The value of the frailty can be quite large, with a range of approximately -6 to +7,
so the estimated coe cient for the individual frailty in the survival model, while small at 0.046
(hazard: exp(0.046 ⇥ f railty)), can have a large e↵ect depending on the value of the subject
specific frailty, with a hazard ratio ranging from a beneficial 0.76, to an increased hazard of
1.38. Note however, that there is quite a wide range of individual frailties for all drug therapies
(see Figure 4.5). The variance of the subject-specific frailty is 10.5, which shows there is a
great deal of unobserved heterogeneity between subjects. To put the results into context, Table
4.4 shows these e↵ects for each treatment combination, comparing the mean, minimum and
maximum frailties of subjects who did not change therapy to those who did. For the group on
initial therapy of TAC alone who did experience a drug failure event, the mean frailty shows
the highest risk of graft failure (mean hazard ratio: 1.25), suggesting that subjects who do not
do well on the ‘gold standard’ TAC are at greatest risk of graft failure.
Results from the best fitting joint model for the HCV negative cohort are shown in Table
4.5. The random e↵ect for the intercept b0i was seen as an important linkage term between
the longitudinal and the graft failure submodels (but again, not in the time-to-drug-failure sub-
model). We saw a lower log(creatinine) over time in female subjects and in subjects on SRL
+ TAC, while a higher log(creatinine) was seen in older subjects, those in fulminant failure at
time of transplant, those who were diabetic at transplant, and those with a higher donor BMI.
This last result, while the e↵ect is small, is nevertheless interesting and could be investigated
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Table 4.3: Posterior means for the log hazard, hazard, standard error and quantiles from the
HCV positive cohort joint model. (ns=not significant; AA = African American; F = female)
Parameter Mean Hazard Std err CI (lower) CI (upper)
Longitudinal submodel:
intercept -0.056 0.026 -0.105 -0.006
slope 0.006 0.0002 0.006 0.006
age in decades 0.004 0.0005 0.003 0.005
fulminant failure 0.361 0.116 0.138 0.589
gender (F) -0.116 0.010 -0.137 -0.096 (ns)
diabetes 0.068 0.018 0.032 0.102
race (AA) 0.032 0.006 0.022 0.044
baseline trt: TAC (ref) — — — —
SRL + TAC 0.012 0.021 -0.028 0.055 (ns)
SRL 0.021 0.036 -0.047 0.089 (ns)
CYA 0.040 0.015 0.010 0.069
CYA + SRL -0.038 0.047 -0.128 0.054 (ns)
⌫1 (variance of b0i) 0.064 0.060 0.067
Time-to-drug-failure submodel:
intercept -9.761 0.097 -9.952 -9.580
baseline trt: TAC alone (ref) — — — —
SRL + TAC 7.522 0.401 6.755 8.310
SRL 3.705 0.609 2.545 4.895
CYA 3.022 0.251 2.527 3.514
CYA + SRL 9.523 1.102 7.436 11.715
 c (variance of ci) 14.929 13.682 16.374
Time-to-graft-failure submodel:
↵ (shape parameter) 0.933 0.028 0.879 0.986
intercept -8.681 0.215 -9.088 -8.263
donor age (decades) 0.016 1.016 0.002 0.012 0.020
race (AA) 0.182 1.200 0.036 0.114 0.248
gender (F) 0.128 0.075 -0.021 0.272 (ns)
previous malignancy 0.451 1.568 0.107 0.239 0.660
baseline trt: TAC (ref) – – – –
SRL + TAC -0.101 0.158 -0.426 0.190 (ns)
SRL -0.462 0.321 -1.146 0.142 (ns)
CYA 0.040 0.108 -0.184 0.243 (ns)
CYA + SRL -0.210 0.373 -0.977 0.493 (ns)
⇢1 0.447 1.564 0.160 0.131 0.770
  0.046 1.047 0.011 0.023 0.068
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Figure 4.4: HCV positive cohort: Histograms of individual log frailties from time-to-drug-
failure model, by whether initial treatment was changed. Positive log frailties are associated
with increased risk of graft failure.
Table 4.4: Summary of frailty e↵ects on graft failure by initial drug therapy for the HCV
positive cohort.
Initial trt No drug failure:Mean (min, max)
Hazard ratio
(min, max) Had drug failure: Mean (min, max)
Hazard ratio
(min, max)
TAC -1.1 (-4.3, 1.3) 0.8, 1.1 4.9 (3.4, 7.1) 1.2, 1.4
SRL + TAC -3.9 (-6.0, -1.3) 0.8, 0.9 1.2 (0.2, 3.5) 1.0, 1.2
SRL -2.2 (-3.9, 0.1) 0.8, 1.0 2.7 (1.7, 4.5) 1.1, 1.2
CYA -2.2 (-4.6, 0.5) 0.8, 1.0 3.0 (1.9, 4.9) 1.1, 1.3
SRL + CYA -4.5 (-5.7, -2.7) 0.8, 0.9 0.6 (-0.02, 2.0) 1.0, 1.1
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Figure 4.5: HCV positive cohort: Histograms of individual log frailties from time-to-drug-
failure model, by initial immunosuppression. Positive log frailties are associated with increased
risk of graft failure.
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further. It is possible that a donor with a higher BMI has more fatty tissue in the liver, result-
ing in more di cult postoperative recovery and higher creatinine. Fatty liver can also lead to
more inflammation and therefore higher doses of immunosuppression. It is also interesting that
this e↵ect was not seen in the HCV positive cohort, possibly because HCV positive subjects
are often counselled against accepting a marginal donor organ with increased risk due to fatty
liver.
Similar to the HCV positive cohort, the only covariates significant in the time-to-drug-
failure submodel were baseline treatment. Being on any initial treatment other than tacrolimus
significantly shortens the time to failure of initial immunosuppressive therapy.
In the graft survival component, no immunosuppressive treatment was significantly di↵er-
ent from the reference drug TAC in terms of impact on graft survival. Risk of graft failure is
increased for those who have HCC, for those who are African American, and for increased
donor age. Gender was kept in the model because it improved DIC. We also tested all variables
for interaction with HCC status and did not find any significant interaction.
Another interesting feature of this analysis is the strong e↵ect of the longitudinal random
e↵ect for log(creatinine) in the graft survival submodel. A one unit increase in log(creatinine)
has a hazard ratio of 1.881 (compared to 1.567 in the HCV positive cohort). The subject-
specific random e↵ect ranges from -0.971 to 1.469, so the hazard can be reduced for negative
random e↵ects (hazard ratio 0.541) or increased to as much as 2.530 for the largest random
e↵ect. It is possible that this HCV negative cohort, having a wider variety of indications for
liver transplant compared to the more homogeneous HCV positive cohort, comprise a group
with diseases that involve more renal decompensation. This leads us to conclude that our
approach taken in Chapter 2 where both cohorts were analyzed together may not be the most
suitable method compared to analyzing them separately as we do here. When grouped by drug
(see Figure 4.6), the intercept random e↵ects are similar to the HCV positive cohort, i.e. no
distinct pattern by drug (compare to Figure 4.3).
The individual frailty ci from the time-to-drug-failure component also has a significant
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Figure 4.6: HCV negative cohort: Histograms of subject-specific intercept random e↵ects
from the longitudinal model, by initial treatment. Positive random e↵ects are associated with
increased risk of graft failure.
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linkage through the association parameter   in the time-to-graft-failure model for the HCV
negative cohort, where it increases survival time for those with negative log frailties, and de-
creases survival time for those with positive log frailties. This result is slightly larger than in
the HCV positive cohort, with a higher risk seen in the negative cohort. Histograms of individ-
ual log frailties grouped by whether a drug change occurred are shown in Figure 4.7, and plots
grouped by initial treatment are shown in Figure 4.8. The value of the frailty also had a wider
range than the HCV positive cohort (-6.5 to +9). Figure 4.8 shows the wide range of individual
frailties for all drug therapies. The variance of the subject-specific frailty was similar to the
positive cohort, showing there is a great deal of unobserved heterogeneity between subjects.
Table 4.6 shows the frailty e↵ects for each treatment combination, comparing the frailties
of subjects who did not change therapy to those who did in the HCV negative cohort. Again
we see the greatest mean frailty in those who had baseline drug failure on TAC.
The overall picture emerging here is that subjects who must discontinue baseline immuno-
suppressive therapy indeed have a poorer outcome, as expected, due to events precipitating
drug failure. The calcineurin-sparing combinations of SRL + CYA and SRL + TAC stand out
(in both cohorts) for having the largest negative mean frailty in those who did not experience
drug failure, and the smallest positive mean frailty in those who did have a drug failure event.
This translates to a lower risk of graft failure regardless of failures in treatment. The e↵ect
of initial drug regime on graft survival must be considered in the context of the time-to-drug-
failure, in order to understand the overall risk to each subject. Stable subjects who do not need
to change baseline treatment have the best outcome, regardless of initial regime. For those who
do have to switch treatments, those at highest risk seem to be the small group who must switch
from TAC alone to some other treatment. This suggests an interesting new area of research into
the dynamics of drug failure on TAC compared to any other treatment, exploring what risks are
specific to this group.
We compared our model to a model using the often employed standard Cox proportional
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Table 4.5: Posterior means for the log hazard, hazard, standard error and quantiles from the
HCV negative cohort joint model.
Parameter Mean Hazard Std err CI (lower) CI (upper)
Longitudinal submodel:
intercept -0.128 0.019 -0.165 -0.091
slope 0.005 0.0002 0.005 0.005
age in decades 0.007 0.0004 0.006 0.008
fulminant failure 0.104 0.018 0.068 0.140
gender (F) -0.154 0.009 -0.173 -0.137
diabetes 0.052 0.016 0.021 0.084
donor BMI 0.0002 0.00007 0.0001 0.0003
baseline trt: TAC alone (ref) — — — —
SRL + TAC -0.041 0.018 -0.078 -0.006
SRL -0.005 0.036 -0.074 0.063 (ns)
CYA 0.015 0.014 -0.011 0.104 (ns)
CYA + SRL 0.014 0.045 -0.073 0.104 (ns)
⌫1 (variance of b0i) 0.075 0.071 0.079
Time-to-drug-failure submodel:
intercept -9.949 0.081 -10.110 -9.792
baseline trt: TAC alone (ref) — — — —
SRL + TAC 7.249 0.336 6.594 7.916
SRL 4.112 0.565 3.029 7.916
CYA 2.643 0.220 2.206 3.075
CYA + SRL 5.844 0.735 4.437 7.356
 c (variance of ci) 15.152 14.085 16.129
Time-to-graft-failure submodel:
↵ (shape parameter) 0.848 0.029 0.789 0.906
intercept -8.134 0.226 -8.584 -7.683
HCC 0.527 1.694 0.135 0.253 0.790
donor age (decades) 0.010 1.011 0.002 0.006 0.014
gender -0.212 0.809 0.077 -0.355 -0.060
baseline trt: TAC (ref) – – – –
SRL + TAC 0.233 0.145 -0.067 0.516 (ns)
SRL -0.199 0.321 -0.836 0.380 (ns)
CYA 0.167 0.112 -0.059 0.388 (ns)
CYA + SRL -0.707 0.516 -1.777 0.211 (ns)
⇢1 0.632 1.881 0.153 0.337 0.929
  0.064 1.066 0.012 0.039 0.088
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Table 4.6: Summary of frailty e↵ects on graft survival by initial drug therapy for the HCV
negative cohort.
Initial trt No drug failure:Mean (min, max)
Hazard ratio
(min, max) Had drug failure: Mean (min, max)
Hazard ratio
(min, max)
TAC -1.3 (-5.0, 1.4) 0.7, 1.1 5.7 (4.4, 9.1) 1.3, 1.8
SRL + TAC -4.8 (-6.5, -1.9) 0.7, 0.9 1.6 (0.6, 4.3) 1.0, 1.3
SRL -3.3 (-4.9, -0.7) 0.7, 1.0 3.3 (2.0, 4.7) 1.1, 1.4
CYA -2.6 (-5.4, 0.5) 0.7, 1.0 4.0 (2.7, 6.8) 1.2, 1.5
SRL + CYA -4.3 (-5.5, -1.3) 0.7, 0.9 2.3 (1.3, 3.4) 1.1, 1.2
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Figure 4.7: HCV negative cohort: Histograms of individual log frailties from time-to-drug-
failure model, by whether drug failure occurred. Positive log frailties are associated with in-
creased risk of graft failure.
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Figure 4.8: HCV negative cohort: Histograms of individual log frailties from time-to-drug-
failure model, by initial immunosuppression. Positive log frailties are associated with increased
risk of graft failure.
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Table 4.7: Results from a standard Cox proportional hazards model for the HCV positive
cohort.
Parameter Coe cient Hazard StdError p
donor age (decades) 0.016 1.016 0.002 < 0.001
log(creatinine) day 0 0.220 1.246 0.070 0.002
gender (F) 0.141 1.152 0.074 0.057
previous malignancy 0.385 1.470 0.111 < 0.001
HCC 0.197 1.217 0.112 0.078
race (AA) 0.163 1.177 0.034 < 0.001
hazards model, with initial treatment as a baseline covariate. We also included log(creatinine)
from the day of transplant as a covariate (86 were missing and so the mean was substituted for
these cases). Using a stepwise procedure, the covariates that remain significant in the model
are similar to both of the joint models presented above, although not identical. The significant
covariates from this model for the HCV positive cohort are presented in Table 4.7. There
were no significant di↵erences in graft survival by baseline treatment for the HCV positive
cohort. The hazards for the significant covariates are very similar to the joint model, and
the standard errors are almost the same. The Cox proportional hazards model has a smaller
e↵ect for log(creatinine) compared to the random e↵ects in the joint model, and the values for
log(creatinine) are smaller (range: -2.3 to 2.9) than the values for the random e↵ects and so this
translates to a smaller e↵ect overall compared to the intercept random e↵ect for creatinine in
the joint model. The joint model also has the added hazard from covariate   and its association
with the frailty ci in the time-to-drug-failure model.
In addition, we compared our model to a Cox proportional hazards model that treats the
use of SRL as a time-dependent covariate. Significant findings are shown in Table 4.8. We
treated SRL as a time-dependent indicator variable where it takes a value of 1 if the subject
is started on SRL (in combination or alone) at transplant, and changes to 0 when the subject
changed treatment. Here we see that the e↵ect for SRL is very significant (p = 0.029) and
the hazard is 1.262 for a subject starting on SRL, and this is a result that we did not see in
either of the previous models. This shows the biased results that are obtained when a time-
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Table 4.8: Results from a Cox proportional hazards model with time-dependent SRL treatment
covariate for the HCV positive cohort.
Parameter Coe cient Hazard StdError p
any SRL (time-dependent) 0.233 1.262 0.107 0.029
donor age (decades) 0.010 1.016 0.002 <0.001
log(creatinine) day 0 0.155 1.168 0.060 0.010
gender (female) 0.126 1.134 0.064 0.048
race (African American) 0.164 1.178 0.029 <0.001
any CYA at baseline 0.634 1.885 0.279 0.023
previous malignancy 0.388 1.474 0.094 <0.001
Table 4.9: Results from a standard Cox proportional hazards model for the HCV negative
cohort.
Parameter Coe cient Hazard StdError p
donor age (decades) 0.009 1.009 0.002 < 0.001
log(creatinine) day 0 0.158 1.171 0.065 0.015
gender (F) -0.172 0.842 0.075 0.022
race (AA) 0.128 1.137 0.042 0.002
previous malignancy 0.724 2.063 0.133 < 0.001
dependent covariate is used in a Cox proportional hazards model when a change in the time-
dependent covariate is also related to outcome. Some of this bias could stem from the dramatic
di↵erences in treatment switching. Subjects who switch treatment early are those with adverse
events who therefore experience more graft failure. Results from other covariates such as donor
age, log(creatinine), gender and previous malignancy are similar to the previously illustrated
models.
The comparisons to the Cox proportional hazards model for the HCV negative cohort show
similar findings. In the HCV negative cohort, when we apply the standard Cox proportional
hazards model to graft survival we get the significant results seen in Table 4.9. Again, baseline
treatment is not significant factor for graft survival in any combination. The e↵ects for donor
age and gender are similar to the joint model.
In the Cox model with time dependent treatment e↵ect for SRL, we again see a greatly
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Table 4.10: Results from a Cox proportional hazards model with time-dependent SRL treat-
ment covariate for the HCV negative cohort.
Parameter Coe cient Hazard StdError p
any SRL (time-dependent) 0.404 1.498 0.095 < 0.001
donor age (decades) 0.008 1.008 0.002 < 0.001
log(creatinine) day 0 0.166 1.180 0.055 0.003
gender (F) -0.177 0.838 0.064 0.006
recipient age (decades) 0.005 1.005 0.003 0.057
HCC 0.226 1.253 0.119 0.059
previous malignancy 0.758 2.133 0.112 < 0.001
race (AA) 0.102 1.108 0.036 0.005
blood type AB -0.309 0.734 0.149 0.038
diabetic 0.239 1.270 0.099 0.016
CYA at baseline 0.276 1.317 0.087 0.002
increased risk for any SRL exposure, with significant results shown in Table 4.10.
This analysis shows that using two time-to-event processes to analyze drug failure and
graft failure, along with a longitudinal component in creatinine, is a valuable approach. The
model has captured the increased risk to graft failure that is present with a sharp change in the
biomarker, or with an adverse event that precipitates drug failure.
4.4 Discussion
Analyzing treatment changes as a time-to-event process is a preferred approach in observa-
tional data analysis since it avoids discarding data. It also avoids the violation of model as-
sumptions such as when treating drug as a time-dependent covariate. Analysis of the two
time-to-event outcomes of drug failure and graft survival using a joint model can account for
dependence between the two processes without making strong assumptions. We allow the im-
portant information contained in the time-to-drug-failure component to influence the hazard
of the time-to-graft failure component. Transplant registry data, with 100% enrolment and
follow up until death, is a valuable and readily available data source that can provide insight
into factors a↵ecting health outcomes after liver transplant. The time-to-drug-failure process
4.4. Discussion 93
acts as a surrogate for time to any adverse event such as infection, rejection, cancer occurrence
or other, that may be unreliably collected in the registry data. This two outcome joint model
describes the data structure well. We believe that use of a straightforward joint survival out-
come model is appropriate for two reasons: first, clinical practice tells us that the association
is strong between the drug failure and graft failure processes, and second, less complex joint
modelling techniques are more likely to be adopted in practice in this field. Joint modelling
is not commonplace in analysis of SRTR data for transplantation, yet despite readily available
and appropriate data, it has only been used in one application of which we are aware (Liu et al.
[2004] for kidney transplant data).
We did not find any significant di↵erences between baseline treatments when compared
to the ‘gold standard’ treatment TAC. However in the context of our joint outcome model,
treatment e↵ects should be interpreted on a subject-specific basis conditional on the frailty. We
found great variability in the frailties. This is an indication that treatments alone are not good
predictors of survival - generally, one treatment does provide better on average survival than
another, yet there is great variability between treatments. When we condition on the frailty,
we will have a better prediction of survival and better understanding of survival by treatment
patterns.
Rather than discard information, we have presented a model that includes all available
data in a way that makes the most scientific sense. The longitudinal component takes into
account factors a↵ecting creatinine level over time. It is a proxy for choice of initial treatment,
mimicking the physician decision process by taking into account all covariates a↵ecting the
evolution of creatinine over time. Degree of renal impairment is an important factor due to
nephrotoxicity of the immunosuppression treatment. Our model o↵ers more insight into the
medical process and makes scientific sense. The subject-specific frailties from the time-to-
drug-failure model account for latent variables that have a significant e↵ect on graft survival,
thus accounting for more of the variance in the data and enhancing our understanding of the
whole process while improving the fit of the model. The information contained in the frailty
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covariate   adds valuable dimension to the model that cannot be accounted for in traditional
models.
A limitation of this data set is the lack of exact dates for treatment failures, and the use
of the interval midpoint is not ideal, however randomized clinical trial data (with exact dates)
is not readily available for public analysis. Statistical bias related to the use of the midpoint
is discussed in Ru¨cker and Messerer [1988] and Odell et al. [1992]. To add recurrent events
to the drug failure model would involve the use of doubly interval censored data that are also
correlated. Furthermore, data on subjects who experience treatment failure more than once
during a data collection interval is not collected with su cient granularity in the SRTR to
allow for a joint outcome analysis with recurrent events in drug failure. An application of
joint modelling techniques to detailed randomized clinical trial data would provide greater
understanding of the problem, since clinical trials normally collect exact dates. With collection
of exact dates, many other time-to-event processes could be examined for their association
with graft survival, such as time to post-transplant diabetes, or time to cancer occurrence or
recurrence.
Another limitation is that important information such as treatment dosage amounts and drug
trough levels are missing from the registry data. Trough levels measure the amount of drug
exposure per patient, which can vary on a subject-specific basis even when subjects are given
the same amount of drug. This is another interesting avenue worth pursuing with transplant
data in joint frailty models.
The authors acknowledge the limitations of this three year retrospective analysis using reg-
istry data. All models in this paper would benefit from more data in the SRL arms. In Chapter
2 we were limited in the size of our dataset because the inclusion of ten years of longitudinal
data increased convergence time. In this chapter we have reduced the longitudinal time-frame
but we suspect that the use of only three years of data in the longitudinal component is not
enough to see a significant e↵ect from the random e↵ect from the ⇣k in the time-to-drug-failure
component. However our goal was met which showed that joint modelling provides added
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value to analysis of survival after liver transplantation.
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Chapter 5
Conclusion and future work
We have presented three papers applying joint modelling techniques to transplant registry data.
We have shown that the longitudinal biomarker creatinine is associated with graft survival,
where higher creatinine levels and a sharp increase in biomarker trajectory are associated with
greater risk of graft failure. We showed that inclusion of biomarkers in the longitudinal com-
ponent can add insight to the post-transplant survival process. Ideally, future work would
include a powerful computational framework such as parallel computing to handle a large
dataset with multiple longitudinal biomarkers and a more detailed examination of change-
point e↵ects. Much more work could be done investigating the relationship between biomarker
change-points and graft failure.
We have also shown that using a two outcome joint survival model to assess e cacy of
immunosuppressive drugs is a valuable approach. A shorter time-to-drug-failure is associated
with greater risk of graft failure in a joint model where individual frailties capture latent fac-
tors related to time on drug. Our novel application of joint time-to-event outcomes to the drug
e cacy issue holds promise. More power could be added to statistical models by harnessing
recurrent event data for drug failure. In addition, the opportunities for the application of joint
outcome models for dynamic predictions in a clinical care setting are exciting. For example,
the decision to switch drug regime is a significant decision-making point for the transplant
physician. A prognosis application for treatment change decisions would be a powerful tool.
Whether to switch treatment, or stay with the current one and wait for retransplant is an im-
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portant question, since there is a risk inherent in a change of immunosuppression protocol and
there is impact on the immune system of the patient. Risks related to treatment changes include
post-transplant lymphoproliferative disease, cancer and death. The framework proposed in this
thesis could be used to assess the risk of a treatment change on an individual basis. While a
powerful computational analysis would be required initially to determine the best model, pre-
dictions for a single patient using the results of the model would be straightforward and simple
in a clinical setting.
Furthermore, joint models are well suited to explore the wealth of information collected
pre-transplant, while a subject is on the waiting list, and to test for the impact of covariates on
the post-transplant process or even to determine ahead of the transplant the optimum treatment
regime for each subject. Biomarker profiles are collected rigorously pre-transplant and this
information can be used to make decisions about post-transplant care.
While we were limited by a number of factors, specifically widely spaced intervals for
data collection and a lack of exact dates for drug regime failures, the significant associations
discovered through joint outcome models using registry data has implications for clinical trials
and clinical care. Joint models provide added value and more information to the analysis, and
with data that is unhindered by wide collection intervals, or lack of exact dates for drug failures,
the results would be interesting.
We have shown that there are pitfalls to avoid in the use of traditional methods for post-
transplant survival analysis, and while the application of unbiased statistical methods is impor-
tant in the analysis of registry data, there is still much work to be done, and the methods for
registry data analysis should continue to borrow strength from discoveries made in the analy-
sis of clinical trial data. It is important that researchers work to allow results and techniques
developed in one area to enhance and enable important discoveries in others. We hope that by
showing the value of joint modelling in transplant registry data it will open up opportunities to
refine and develop new methods with more detailed clinical trial or clinical care data.
These results are not limited to transplantation, and can be applied generally to other reg-
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istries in di↵erent areas of medicine such as cancer and mental health.
Curriculum Vitae
M. Elizabeth Renouf
Education M.Sc., Statistics, 2008-2010
Collaborative Program in Biostatistics
Department of Statistical & Actuarial Sciences
University of Western Ontario
B.Sc., Statistics, 2004-2007
Department of Statistical & Actuarial Sciences
University of Western Ontario
M.A., Classics, 1993-1995
Department of Classical Studies
University of Western Ontario
B.A., Classical Studies and Latin, 1989-1993
Department of Classical Studies
University of Western Ontario
Honours and Awards
NSERC Vanier CGS D 2010-2013
NSERC CGS M, 2009
NSERC USRA, 2006
102
103
Publications and Presentations
Bellhouse DR, Renouf EM, Raut R, Bauer MA. (2009) De Moivre’s Knowledge Com-
munity: an Analysis of the Subscription List to the Miscellanea Analytica. Notes and
Records of the Royal Society 63, 137-162.
Stanford DA, Renouf EM, McAlister VC. (2008) Waiting for Liver Transplantation in
Canada: Wait List History 2000-04 and Sensitivity Analysis for the Future. Health Care
Management Science Jun.11(2) 1184-195.
McAlister VC, Davenport E, Renouf E. (2007) Cholecystectomy deferral in patients with
endoscopic sphincterotomy. Cochrane Database Syst Rev. Oct 17;(4):CD006233.
Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. (2006) Cy-
closporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev.
Oct 18;(4):CD005161.
McAlister VC, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud LL. (2006) Cy-
closporin versus Tacrolimus as Primary Immunosuppressant After Liver Transplantation:
A Meta-Analysis. American Journal of Transplantation 6(7): 1578-1585.
Renouf E. and McAlister VC. (2004) Old Drugs for new: Contemporary Immunosup-
pressant Development. Medicinal Chemistry Reviews Online 1, 1-5.
Arlen D, Cole E, Hebert D, Holland D, Jevnikar A, Knoll G, Zaltzman J, Renouf E,
Feldman P. (2004) Study of Cardiovascular Outcomes in Renal Transplantation (SCORe).
Presented at the Canadian Society of Transplantation Annual Scientific Meeting.
Renouf E, McMichael JP, McAlister VC. (2003) Predicting Sirolimus Doses and Levels
from Prior or Concurrent Tacrolimus or Cyclosporine Dose/Level Using the Intelligent
Dosing System. Presented at the American Transplant Congress, Washington, D.C.
Jevnikar A, Cole E, Zaltzman J, Arlen D, Knoll G, Hebert D, Renouf E, Sim D. (2001)
Selection of Tacrolimus for Induction and Conversion Therapy: A Retrospective Analysis
of the Clinical Indications and E↵ectiveness in Non-Study Renal Transplant Patients in
Ontario, Canada. Presented at the 2nd International Congress on Immunosuppression,
San Diego, California.
104 Chapter 5. Conclusion and future work
July 6, 2016
